<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>ACC/AHA Versus ESC Guidelines on Dual&amp;nbsp;Antiplatelet Therapy</title><meta name="author" content="Davide Capodanno MD PhD"/><meta name="description" content="Journal of the American College of Cardiology, 72 (2018) 2915-2931. doi:10.1016/j.jacc.2018.09.057"/><style type="text/css"> * {margin:0; padding:0; text-indent:0; }
 .s1 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 5pt; }
 .s2 { color: black; font-family:Calibri, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 5pt; }
 .s3 { color: #002C5B; font-family:Arial, sans-serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 7.5pt; }
 .s4 { color: #002C5B; font-family:"Lucida Sans", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt; }
 .s5 { color: #002C5B; font-family:"Lucida Sans", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 19pt; }
 .s6 { color: #002C5B; font-family:Arial, sans-serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 12.5pt; }
 .s7 { color: #002C5B; font-family:"Lucida Sans", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt; }
 .p, p { color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt; margin:0pt; }
 .s8 { color: #007FAC; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt; }
 .s9 { color: #007FAC; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt; }
 .s10 { color: black; font-family:"Century Gothic", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt; }
 .s11 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt; }
 .s12 { color: #FFF; font-family:"Lucida Sans", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt; }
 .s13 { color: #002C5B; font-family:"Perpetua Titling MT", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 47.5pt; }
 .s14 { color: #007FAC; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt; }
 .s15 { color: #E22A2C; font-family:Verdana, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s16 { color: #E22A2C; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s17 { color: #E22A2C; font-family:Verdana, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s18 { color: #E22A2C; font-family:Georgia, serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s19 { color: #E22A2C; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s20 { color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s21 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s22 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s24 { color: #007FAC; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7pt; }
 .s25 { color: #E12A2C; font-family:"Lucida Sans", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s26 { color: #E12A2C; font-family:"Lucida Sans", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 5.5pt; }
 .s27 { color: black; font-family:Tahoma, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 5.5pt; }
 .s28 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt; }
 .s29 { color: #007FAC; font-family:Tahoma, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt; }
 .s30 { color: #007FAC; font-family:Tahoma, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt; }
 .s31 { color: #002C5B; font-family:"Lucida Sans", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .s32 { color: #002C5B; font-family:"Lucida Sans", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7pt; }
 .s33 { color: #E12A2C; font-family:"Lucida Sans", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 5.5pt; }
 .s34 { color: #002C5B; font-family:Tahoma, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s35 { color: black; font-family:Tahoma, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 5.5pt; }
 .s36 { color: black; font-family:"Century Gothic", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s37 { color: black; font-family:Arial, sans-serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s38 { color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s39 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s40 { color: black; font-family:"Lucida Sans", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s41 { color: black; font-family:"Century Gothic", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 5pt; }
 .s42 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 5pt; }
 .s43 { color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt; }
 .s44 { color: black; font-family:"Lucida Sans", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt; }
 .s45 { color: #002C5B; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s47 { color: black; font-family:"Trebuchet MS", sans-serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 7.5pt; }
 .s48 { color: #4C4D4F; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s49 { color: black; font-family:Tahoma, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s50 { color: #FFF; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s51 { color: #4C4D4F; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 4pt; vertical-align: -2pt; }
 .s52 { color: #007FAC; font-family:Tahoma, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s53 { color: #4C4D4F; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7pt; }
 .s54 { color: #4C4D4F; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 5pt; vertical-align: -2pt; }
 .s55 { color: #FFF; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7pt; }
 .s56 { color: #E12A2C; font-family:"Lucida Sans", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8.5pt; }
 .s57 { color: #002C5B; font-family:Tahoma, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .s58 { color: #4C4D4F; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9.5pt; }
 .s59 { color: #FFF; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9.5pt; }
 .s60 { color: #4C4D4F; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9.5pt; vertical-align: -3pt; }
 .s61 { color: #4C4D4F; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9.5pt; vertical-align: -1pt; }
 .s62 { color: #FFF; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9.5pt; vertical-align: 1pt; }
 .s63 { color: #FFF; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9.5pt; vertical-align: -5pt; }
 .s64 { color: #FFF; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9.5pt; vertical-align: -1pt; }
 .s65 { color: #4C4D4F; font-family:Tahoma, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7pt; }
 .s66 { color: #4C4D4F; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9.5pt; vertical-align: -7pt; }
 .s67 { color: #4C4D4F; font-family:Tahoma, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7pt; vertical-align: 1pt; }
 .s68 { color: #FFF; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9.5pt; vertical-align: -4pt; }
 .s69 { color: #4C4D4F; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9.5pt; vertical-align: 3pt; }
 .s70 { color: #4C4D4F; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9.5pt; vertical-align: 8pt; }
 .s71 { color: #4C4D4F; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9.5pt; vertical-align: -2pt; }
 .s72 { color: black; font-family:Tahoma, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7pt; }
 .s73 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7pt; }
 .s74 { color: #007FAC; font-family:Tahoma, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 5.5pt; }
 .s75 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: underline; font-size: 7.5pt; }
 .s76 { color: #4C4D4F; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8.5pt; }
 .s77 { color: #5CA5DB; font-family:Tahoma, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7pt; }
 .s78 { color: #4C4D4F; font-family:Tahoma, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .s79 { color: #FFF; font-family:Tahoma, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s80 { color: #FFF; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 4pt; }
 .s81 { color: #4C4D4F; font-family:Tahoma, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s82 { color: #4C4D4F; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 4pt; }
 .s83 { color: #007FAC; font-family:Tahoma, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .a, a { color: #007FAC; font-family:"Century Gothic", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s85 { color: #007FAC; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s88 { color: #007FAC; font-family:Arial, sans-serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s89 { color: #007FAC; font-family:"Century Gothic", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s91 { color: #002C5B; font-family:"Lucida Sans", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s92 { color: black; font-family:Tahoma, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 li {display: block; }
 #l1 {padding-left: 0pt; }
 #l1> li>*:first-child:before {content: "• "; color: #002C5B; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 li {display: block; }
 #l2 {padding-left: 0pt; }
 #l2> li>*:first-child:before {content: "• "; color: #002C5B; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 li {display: block; }
 #l3 {padding-left: 0pt; }
 #l3> li>*:first-child:before {content: "• "; color: #002C5B; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 li {display: block; }
 #l4 {padding-left: 0pt; }
 #l4> li>*:first-child:before {content: "• "; color: #002C5B; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 li {display: block; }
 #l5 {padding-left: 0pt; }
 #l5> li>*:first-child:before {content: "• "; color: #002C5B; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 li {display: block; }
 #l6 {padding-left: 0pt; }
 #l6> li>*:first-child:before {content: "• "; color: #002C5B; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 li {display: block; }
 #l7 {padding-left: 0pt; }
 #l7> li>*:first-child:before {content: "• "; color: #002C5B; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 li {display: block; }
 #l8 {padding-left: 0pt; }
 #l8> li>*:first-child:before {content: "• "; color: #002C5B; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 li {display: block; }
 #l9 {padding-left: 0pt; }
 #l9> li>*:first-child:before {content: "• "; color: #002C5B; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 li {display: block; }
 #l10 {padding-left: 0pt; }
 #l10> li>*:first-child:before {content: "• "; color: #002C5B; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 li {display: block; }
 #l11 {padding-left: 0pt; }
 #l11> li>*:first-child:before {content: "• "; color: #002C5B; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 li {display: block; }
 #l12 {padding-left: 0pt; }
 #l12> li>*:first-child:before {content: "• "; color: #002C5B; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 li {display: block; }
 #l13 {padding-left: 0pt; }
 #l13> li>*:first-child:before {content: "• "; color: #002C5B; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 li {display: block; }
 #l14 {padding-left: 0pt; }
 #l14> li>*:first-child:before {content: "• "; color: #002C5B; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 li {display: block; }
 #l15 {padding-left: 0pt;counter-reset: q1 21; }
 #l15> li>*:first-child:before {counter-increment: q1; content: counter(q1, upper-latin)" "; color: black; font-style: normal; font-weight: normal; text-decoration: none; }
 #l15> li:first-child>*:first-child:before {counter-increment: q1 0;  }
 #l16 {padding-left: 0pt;counter-reset: q2 2; }
 #l16> li>*:first-child:before {counter-increment: q2; content: counter(q2, upper-latin)") "; color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt; }
 #l16> li:first-child>*:first-child:before {counter-increment: q2 0;  }
 li {display: block; }
 #l17 {padding-left: 0pt;counter-reset: r1 1; }
 #l17> li>*:first-child:before {counter-increment: r1; content: counter(r1, decimal)". "; color: black; font-family:Tahoma, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 #l17> li:first-child>*:first-child:before {counter-increment: r1 0;  }
 table, tbody {vertical-align: top; overflow: visible; }
</style></head><body><p class="s1" style="padding-top: 3pt;padding-left: 113pt;text-indent: 0pt;text-align: left;"><a name="bookmark0">J O U R NA L O F T HE A M E R I C AN CO LL EG E O F C AR DI O L O G Y VOL. 7 2 , N O . 23, 2 018 </a></p><p class="s2" style="padding-top: 4pt;padding-left: 113pt;text-indent: 0pt;line-height: 165%;text-align: left;">ª <span class="s1">201 8 BY TH E A MERICA N C OLL E G E O F CA RDIOL O G Y FOU N D A T I ON P U BLIS HED B Y E L S EVIER </span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="343" height="0" alt="image" src="j.jacc.2018.09.057/Image_001.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s3" style="padding-top: 4pt;padding-left: 113pt;text-indent: 0pt;text-align: left;">JACC <span class="s4">GUIDELINE COMPARISON</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="32" height="32" alt="image" src="j.jacc.2018.09.057/Image_002.png"/></span></p><p class="s5" style="padding-left: 113pt;text-indent: 0pt;line-height: 107%;text-align: left;">ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy</p><p class="s6" style="padding-top: 5pt;padding-left: 113pt;text-indent: 0pt;text-align: left;">JACC <span class="s7">Guideline Comparison</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s9" style="padding-top: 6pt;padding-left: 113pt;text-indent: 0pt;line-height: 140%;text-align: left;"><a href="#bookmark24" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">Davide Capodanno, MD, PHD,</a><a href="#bookmark24" class="s8">a</a> <a href="#bookmark25" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">Fernando Alfonso, MD, PHD,</a><a href="#bookmark25" class="s8">b</a> <a href="#bookmark25" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">Glenn N. Levine, MD,</a><a href="#bookmark25" class="s8">c</a> <a href="#bookmark26" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">Marco Valgimigli, MD, PHD,</a>d <a href="#bookmark26" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">Dominick J. Angiolillo, MD, PHD</a><a href="#bookmark26" class="s8">e</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 113pt;text-indent: 0pt;text-align: left;"><span><img width="0" height="214" alt="image" src="j.jacc.2018.09.057/Image_003.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s10" style="padding-left: 8pt;text-indent: 0pt;line-height: 130%;text-align: left;">Dual antiplatelet therapy (DAPT) is the cornerstone of pharmacological treatment aimed at preventing the athero- thrombotic complications in patients with a variety of coronary artery disease (CAD) manifestations. Prescribers of DAPT are confronted with a number of challenges that include selecting the appropriate P2Y12 inhibitor and determining the optimal duration of DAPT with the scope of minimizing the risk of ischemic and bleeding complications in light of each patient<span class="s11">’</span>s clinical characteristic and circumstance. Recently, a guideline writing committee from the American College of Cardiology/American Heart Association (ACC/AHA) and a task force from the European Society of Cardiology (ESC) released their respective focused update recommendations on <span class="s11">“</span>Duration of DAPT in Patients with CAD<span class="s11">” </span>(ACC/AHA) and <span class="s11">“</span>DAPT in CAD<span class="s11">” </span>(ESC). This paper aims to review the ACC/AHA and ESC updates for DAPT to delineate common domains, consistent messages, and differences in recommended management strategies across the Atlantic.</p><p class="s10" style="padding-left: 8pt;text-indent: 0pt;text-align: left;">(J Am Coll Cardiol 2018;72:2915<span class="s11">–</span>31) © 2018 by the American College of Cardiology Foundation.</p><p style="text-indent: 0pt;text-align: left;"/><p class="s12" style="padding-top: 1pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">ABSTRACT</p><p style="text-indent: 0pt;text-align: left;"/><p class="s13" style="text-indent: 0pt;line-height: 50pt;text-align: left;">D</p><p style="text-indent: 0pt;text-align: left;"/><p style="padding-top: 5pt;padding-left: 152pt;text-indent: 0pt;line-height: 140%;text-align: justify;">ual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a platelet P2Y12 inhibitor, is the cornerstone of phar-</p><p class="s9" style="padding-left: 113pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a href="#bookmark36" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">macological treatment aimed at preventing athero- thrombotic complications in patients with a variety of coronary artery disease (CAD) manifestations </a>(1)<span style=" color: #000;">. A patient with CAD may require DAPT in the context of myocardial revascularization (e.g., percutaneous coronary intervention [PCI] or coronary artery bypass grafting [CABG], after an acute coronary syndrome</span></p><p style="padding-top: 5pt;padding-left: 9pt;text-indent: 0pt;line-height: 140%;text-align: justify;">[ACS]) (e.g., non<span class="s11">–</span><a href="#bookmark37" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">ST-segment elevation acute coro- nary syndrome [NSTE-ACS] or ST-segment elevation myocardial infarction [STEMI]), or for secondary pre- vention in high-risk clinical presentations (e.g., stable CAD in a patient with a history of myocardial infarc- tion [MI]) </a><a href="#bookmark37" class="s8">(2</a><a href="#bookmark37" class="s14">–</a><span style=" color: #007FAC;">4)</span>. In each of these intersecting sce- narios, decision-making of DAPT prescribers is confronted with a number of challenges that essen- tially include, but  are not limited to, selecting the P2Y12 inhibitor and determining the optimal duration</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 113pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="387" height="0" alt="image" src="j.jacc.2018.09.057/Image_004.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 45pt;text-indent: 0pt;text-align: left;"><span><img width="46" height="40" alt="image" src="j.jacc.2018.09.057/Image_005.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 25pt;text-indent: 0pt;line-height: 130%;text-align: left;"><a href="https://s3.amazonaws.com/ADFJACC/JACC7223/JACC7223_fustersummary_06" class="s15" target="_blank">Listen to this manuscript</a><a href="https://s3.amazonaws.com/ADFJACC/JACC7223/JACC7223_fustersummary_06" class="s16" target="_blank">’</a><a href="https://s3.amazonaws.com/ADFJACC/JACC7223/JACC7223_fustersummary_06" class="s15" target="_blank">s audio summary by</a></p><p class="s17" style="padding-bottom: 3pt;padding-left: 25pt;text-indent: 0pt;line-height: 129%;text-align: left;"><a href="https://s3.amazonaws.com/ADFJACC/JACC7223/JACC7223_fustersummary_06" class="s18" target="_blank">JACC </a><a href="https://s3.amazonaws.com/ADFJACC/JACC7223/JACC7223_fustersummary_06" class="s15" target="_blank">Editor-in-Chief </a>Dr. Valentin Fuster<span class="s19">.</span></p><p style="padding-left: 40pt;text-indent: 0pt;text-align: left;"><span><img width="62" height="62" alt="Unlabelled image" title="Unlabelled image" src="j.jacc.2018.09.057/Image_006.gif"/></span></p><p class="s20" style="padding-top: 6pt;padding-left: 7pt;text-indent: 0pt;line-height: 138%;text-align: justify;"><a name="bookmark24">From the aDivision of Cardiology, CAST, P.O. </a><span class="s21">“</span>G. Rodolico,<span class="s21">” </span>Azienda Ospedaliero-Universitaria <span class="s21">“</span>Policlinico-Vittorio Emanuele,<span class="s21">” </span>University of Catania, Catania, Italy; bDepartment of Cardiology, Hospital Universitario La Princesa, Madrid, Spain; cDepartment of Medicine, Baylor College of Medicine, Houston, Texas; dBern University Hospital, Bern, Switzerland; and the eDivision of Car- diology, University of Florida College of Medicine, Jacksonville, Florida. Dr. Capodanno has served on the advisory board of and received speaker<span class="s21">’</span>s honoraria from AstraZeneca and Bayer. Dr. Valgimigli has received grants from The Medicines Company, Terumo, and AstraZeneca; and has received personal fees from Terumo, St. Jude Vascular, and Abbott Vascular. Dr. Angiolillo has received consulting fees or honoraria from Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PLx Pharma, P<span class="s22">ﬁ</span>zer, Sano<span class="s22">ﬁ</span>, and The Medicines Com- pany; has received payment for review activities from CeloNova and St. Jude Medical; has received institutional payments for grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, and Renal Guard Solutions; and has received funding from the Scott R. MacKenzie Foundation and the National Institutes of Health/National Center for Advancing Translational Sciences Clinical and Translational Science Award to the University of Florida UL1 TR000064 and NIH/NHGRI U01 HG007269. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.<a name="bookmark25">&zwnj;</a><a name="bookmark26">&zwnj;</a></p><p class="s20" style="padding-top: 5pt;padding-left: 7pt;text-indent: 0pt;text-align: justify;">Manuscript received May 9, 2018; revised manuscript received September 5, 2018, accepted September 8, 2018.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 113pt;text-indent: 0pt;text-align: left;"><a href="https://doi.org/10.1016/j.jacc.2018.09.057" style=" color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7pt;" target="_blank">ISSN 0735-1097/$36.00 </a><a href="https://doi.org/10.1016/j.jacc.2018.09.057" class="s24" target="_blank">https://doi.org/10.1016/j.jacc.2018.09.057</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s25" style="padding-top: 6pt;padding-left: 38pt;text-indent: 0pt;line-height: 156%;text-align: left;"><a name="bookmark1">ABBR EVIAT I ONS AND A CRO N Y M S</a><a name="bookmark2">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s26" style="padding-left: 38pt;text-indent: 0pt;line-height: 134%;text-align: left;">ACC <span class="s27">= American College of Cardiology</span></p><p class="s26" style="padding-top: 4pt;padding-left: 38pt;text-indent: 0pt;line-height: 134%;text-align: left;">AHA <span class="s27">= American Heart Association</span></p><p class="s26" style="padding-top: 4pt;padding-left: 38pt;text-indent: 0pt;text-align: left;">CAD <span class="s27">= coronary artery disease</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s26" style="padding-left: 38pt;text-indent: 0pt;line-height: 134%;text-align: left;">COR <span class="s27">= Class of Recommendation</span></p><p class="s26" style="padding-top: 4pt;padding-left: 38pt;text-indent: 0pt;line-height: 134%;text-align: left;">DAPT <span class="s27">= dual antiplatelet therapy</span></p><p class="s26" style="padding-top: 4pt;padding-left: 38pt;text-indent: 0pt;line-height: 134%;text-align: left;">ESC <span class="s27">= European Society of Cardiology</span></p><p class="s26" style="padding-top: 4pt;padding-left: 38pt;text-indent: 0pt;text-align: left;">LOE <span class="s27">= Level of Evidence</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s26" style="padding-left: 38pt;text-indent: 0pt;text-align: left;">MI <span class="s27">= myocardial infarction</span></p><p class="s26" style="padding-top: 6pt;padding-left: 38pt;text-indent: 0pt;line-height: 134%;text-align: left;">PCI <span class="s27">= percutaneous coronary intervention</span></p><p class="s26" style="padding-top: 4pt;padding-left: 38pt;text-indent: 0pt;line-height: 134%;text-align: left;">STEMI <span class="s27">= ST-segment elevation myocardial infarction</span></p><p style="padding-top: 5pt;padding-left: 20pt;text-indent: 0pt;line-height: 140%;text-align: justify;">of DAPT with the scope of minimizing the risk of ischemic and bleeding complications in light of each patient<span class="s11">’</span><a href="#bookmark38" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">s clinical character- istic and circumstance </a><span style=" color: #007FAC;">(5)</span>.</p><p style="text-indent: 0pt;text-align: left;"><span><img width="0" height="287" alt="image" src="j.jacc.2018.09.057/Image_007.png"/></span></p><p style="padding-left: 20pt;text-indent: 9pt;line-height: 140%;text-align: justify;">Clinical practice guidelines are written under the auspices of national or interna- tional societies, such as the American College of Cardiology (ACC), the American Heart As- sociation (AHA), and the European Society of Cardiology (ESC), to provide physicians with practical recommendations for the best management strategies of patients with given conditions. In both the United States and Europe, DAPT has for years been a sub- chapter or a brief mention in the guidelines for the management of patients presenting with NSTE-ACS, STEMI, or stable CAD, and those undergoing myocardial revasculariza- tion or noncardiac surgery. More recently, a</p><p style="padding-top: 5pt;padding-left: 9pt;text-indent: 0pt;line-height: 139%;text-align: justify;">recommendations for formulating and issuing ESC guidelines by a selection of experts in the <span class="s28">ﬁ</span><a href="#bookmark40" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">eld, based on a comprehensive review of the published evidence </a><span style=" color: #007FAC;">(7)</span><a href="#bookmark27" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">. This paper aims to review and compare the ACC/ AHA and ESC updates for DAPT to delineate common domains, consistent messages, and differences in recommended management strategies across the Atlantic. Meanings and suggested phrasings of Class of Recommendation (COR) and Level of Evidence (LOE) for each update are summarized in </a><a href="#bookmark28" class="s29">Tables 1 and </a><span class="s30">2</span>. While the interpretation of the COR I and III is straightforward, the COR IIa and IIb imply con- <span class="s28">ﬂ</span>icting evidence or divergence of opinion regarding the relative bene<span class="s28">ﬁ</span>t and risk of a given treatment or procedure. In general, when the COR is IIa, the weight of the evidence or opinion is in favor of the treatment or procedure, whereas a COR IIb implies that there is not enough data to make a more de<span class="s28">ﬁ</span>nitive recommendation, the data may be some-</p><p style="padding-left: 109pt;text-indent: 0pt;line-height: 139%;text-align: justify;">guideline writing committee from the ACC/AHA and a task force from the ESC released their respective focused update recommendations on <span class="s11">“</span>Duration of DAPT in Patients with CAD<span class="s11">” </span>(ACC/AHA), published in 2016, and <span class="s11">“</span>DAPT in CAD<span class="s11">” </span><a href="#bookmark39" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">(ESC, in collaboration with the European Association for Cardio-Thoracic Sur- gery), published in 2017 </a><span style=" color: #007FAC;">(6,7)</span>.</p><p style="padding-left: 109pt;text-indent: 9pt;line-height: 140%;text-align: justify;">The need for dedicated DAPT updates is well justi<span class="s28">ﬁ</span>ed by the large amount of data and new infor- mation generated in the <span class="s28">ﬁ</span>eld over the past few years. As expected, the ACC/AHA and ESC updates contain large areas of overlap as well as some differences. Differences were largely explained by the different times of publication of the 2 documents rather than a different interpretation of the evidence available at that time. Indeed, the 2017 ESC update was published</p><p style="padding-left: 109pt;text-indent: 0pt;line-height: 140%;text-align: justify;">1.5 years after the 2016 ACC/AHA update, thus allowing for more chance to incorporate the newest data, and also to put into perspective data that were new when the 2016 ACC/AHA document was pub- lished. With respect to antiplatelet therapy, the ESC/European Association for Cardio-Thoracic Sur- gery guidelines for myocardial revascularization, released in 2018, essentially re<span class="s28">ﬂ</span><a href="#bookmark41" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">ect the recommen- dations provided in the 2017 ESC update on DAPT with few notable exceptions mentioned in the following text </a><span style=" color: #007FAC;">(8)</span>.</p><p class="s9" style="padding-left: 109pt;text-indent: 9pt;line-height: 140%;text-align: justify;"><a href="#bookmark39" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">From a methodological standpoint, the 2016 ACC/ AHA update was built around 3 critical questions related to the duration of DAPT, which served as the basis for a formal systematic review and evaluation of the available data </a>(6)<span style=" color: #000;">. The writing group consisted of the chairs, vice-chairs, and members of previous guidelines tackling the topic of DAPT. Conversely, the 2017 ESC update was built in keeping with</span></p><p style="padding-left: 9pt;text-indent: 0pt;line-height: 140%;text-align: justify;">what contradictory, or the bene<span class="s28">ﬁ</span>t may be extremely modest. Notably, despite some subtle differences that exist in criteria for and phrasing of COR and LOE in the ACC/AHA and ESC updates, the general meaning is essentially consistent. Common themes in both the ACC/AHA and ESC focused updates include risk strati<span class="s28">ﬁ</span><a href="#bookmark39" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">cation, the type and initial timing of P2Y12 inhibitor administration, the duration of DAPT in different patient scenarios, the use of pro- ton pump inhibitors, and the management of anti- platelet therapy in patients on oral anticoagulation </a><span style=" color: #007FAC;">(6,7)</span>. Some areas of controversy (e.g., drug-to-drug interactions, platelet function and genetic testing, bridging of antiplatelet agents in the perioperative period, and dual-pathway inhibition therapy with both antiplatelet and anticoagulant agents) are either not addressed or only brie<span class="s28">ﬂ</span>y discussed due to lack of conclusive data supporting speci<span class="s28">ﬁ</span>c recommendations.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s31" style="padding-left: 9pt;text-indent: 0pt;text-align: justify;">GENERAL CONCEPTS</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 9pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="135" height="0" alt="image" src="j.jacc.2018.09.057/Image_008.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s32" style="padding-left: 9pt;text-indent: 0pt;text-align: justify;">RISK STRATIFICATION FOR ISCHEMIC AND</p><p class="s9" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><span class="s32">BLEEDING EVENTS. </span><a href="#bookmark39" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">Risk characterization for ischemic or bleeding complications is an overriding concept in both the ACC/AHA and ESC updates, although it is recognized that many patients are at high risk for both types of event </a>(6,7)<a href="#bookmark42" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">. In both docu- ments, the DAPT score, derived from the DAPT trial </a>(9)<span style=" color: #000;">, is discussed as a way to assess the risk/bene</span><span class="s28">ﬁ</span><a href="#bookmark43" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">t of prolonging DAPT beyond 12 months from PCI, based on the contribution of a number of risk factors </a>(10)<span style=" color: #000;">. The prediction rule assigns positive integer values to diabetes mellitus, current cigarette use, prior PCI or prior MI, congestive heart failure or left ventricular</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:41.964pt" cellspacing="0"><tr style="height:18pt"><td style="width:424pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="4" bgcolor="#DEE9F7"><p class="s33" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="bookmark3">TABLE 1 </a><span class="s34">Comparative Meaning and Suggested Phrasing of Classes of Recommendation in the ACC/AHA and ESC Guidelines</span><a name="bookmark27">&zwnj;</a></p></td></tr><tr style="height:13pt"><td style="width:36pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:71pt;border-bottom-style:solid;border-bottom-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:165pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s35" style="padding-top: 3pt;padding-left: 69pt;padding-right: 69pt;text-indent: 0pt;text-align: center;">ACC/AHA</p></td><td style="width:152pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s35" style="padding-top: 3pt;padding-left: 71pt;padding-right: 68pt;text-indent: 0pt;text-align: center;">ESC</p></td></tr><tr style="height:69pt"><td style="width:36pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt" bgcolor="#DEE9F7"><p class="s36" style="padding-top: 1pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">COR I</p></td><td style="width:71pt;border-top-style:solid;border-top-width:1pt" bgcolor="#DEE9F7"><p class="s36" style="padding-top: 1pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">Meaning</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s36" style="padding-left: 8pt;text-indent: 0pt;text-align: left;">Suggested phrasing</p></td><td style="width:165pt;border-top-style:solid;border-top-width:1pt" bgcolor="#DEE9F7"><p class="s36" style="padding-left: 8pt;text-indent: 0pt;text-align: left;">Bene<span class="s37">ﬁ</span>t <span class="s38">&gt;&gt;&gt; </span>risk</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l1"><li><p class="s36" style="padding-left: 17pt;text-indent: -9pt;text-align: left;">Is recommended</p></li><li><p class="s36" style="padding-left: 17pt;text-indent: -9pt;text-align: left;">Is indicated/useful/effective/bene<span class="s37">ﬁ</span>cial</p></li><li><p class="s36" style="padding-left: 17pt;text-indent: -9pt;text-align: left;">Should be performed/administered/other</p></li><li><p class="s36" style="padding-left: 17pt;text-indent: -9pt;text-align: left;">A is recommended/indicated in preference to B</p></li><li><p class="s36" style="padding-left: 17pt;text-indent: -9pt;text-align: left;">A should be chosen over B</p></li></ul></td><td style="width:152pt;border-top-style:solid;border-top-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DEE9F7"><p class="s36" style="padding-top: 1pt;padding-left: 18pt;padding-right: 4pt;text-indent: -9pt;line-height: 109%;text-align: left;">Evidence and/or general agreement that a given treatment or procedure is bene<span class="s37">ﬁ</span>cial, useful, effective</p><ul id="l2"><li><p class="s36" style="padding-top: 2pt;padding-left: 17pt;text-indent: -9pt;text-align: left;">Is recommended</p></li><li><p class="s36" style="padding-left: 17pt;text-indent: -9pt;text-align: left;">Is indicated</p></li></ul></td></tr><tr style="height:85pt"><td style="width:36pt;border-left-style:solid;border-left-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 4pt;padding-right: 6pt;text-indent: 0pt;text-align: center;">COR IIa</p></td><td style="width:71pt"><p class="s36" style="padding-top: 1pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">Meaning</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s36" style="padding-left: 8pt;text-indent: 0pt;text-align: left;">Suggested phrasing</p></td><td style="width:165pt"><p class="s36" style="padding-left: 8pt;text-indent: 0pt;text-align: left;">Bene<span class="s37">ﬁ</span>t <span class="s38">&gt;&gt; </span>risk (<span class="s39">“</span>routine practice<span class="s39">”</span>)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l3"><li><p class="s36" style="padding-left: 17pt;text-indent: -9pt;text-align: left;">Is reasonable</p></li><li><p class="s36" style="padding-left: 17pt;text-indent: -9pt;text-align: left;">Can be useful, effective, bene<span class="s37">ﬁ</span>cial</p></li><li><p class="s36" style="padding-left: 17pt;padding-right: 35pt;text-indent: -9pt;line-height: 109%;text-align: left;">A is probably recommended/indicated in preference to B</p></li><li><p class="s36" style="padding-left: 17pt;text-indent: -9pt;line-height: 7pt;text-align: left;">It is reasonable to choose A over B</p></li></ul></td><td style="width:152pt;border-right-style:solid;border-right-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 18pt;padding-right: 4pt;text-indent: -9pt;line-height: 108%;text-align: left;">Con<span class="s37">ﬂ</span>icting evidence and/or a divergence of opinion about the usefulness/ef<span class="s37">ﬁ</span>cacy of the given treatment or procedure: weight of evidence/opinion is in favor of usefulness/ ef<span class="s37">ﬁ</span>cacy</p><ul id="l4"><li><p class="s36" style="padding-top: 2pt;padding-left: 17pt;text-indent: -9pt;text-align: left;">Should be considered</p></li></ul></td></tr><tr style="height:85pt"><td style="width:36pt;border-left-style:solid;border-left-width:1pt" bgcolor="#DEE9F7"><p class="s36" style="padding-top: 1pt;padding-left: 4pt;padding-right: 6pt;text-indent: 0pt;text-align: center;">COR IIb</p></td><td style="width:71pt" bgcolor="#DEE9F7"><p class="s36" style="padding-top: 1pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">Meaning</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s36" style="padding-left: 8pt;text-indent: 0pt;text-align: left;">Suggested phrasing</p></td><td style="width:165pt" bgcolor="#DEE9F7"><p class="s36" style="padding-top: 1pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">Bene<span class="s37">ﬁ</span>t <span class="s40">$ </span>risk (<span class="s39">“</span>case by case decision<span class="s39">”</span>)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l5"><li><p class="s36" style="padding-left: 17pt;text-indent: -9pt;text-align: left;">May/might be reasonable</p></li><li><p class="s36" style="padding-left: 17pt;text-indent: -9pt;text-align: left;">May/might be considered</p></li><li><p class="s36" style="padding-left: 17pt;padding-right: 58pt;text-indent: -9pt;line-height: 8pt;text-align: left;">Usefulness/effectiveness is unknown/unclear/uncertain or not well established</p></li></ul></td><td style="width:152pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DEE9F7"><p class="s36" style="padding-top: 1pt;padding-left: 18pt;padding-right: 7pt;text-indent: -9pt;line-height: 108%;text-align: left;">Con<span class="s37">ﬂ</span>icting evidence and/or a divergence of opinion about the usefulness/ef<span class="s37">ﬁ</span>cacy of the given treatment or procedure: usefulness/ ef<span class="s37">ﬁ</span>cacy is less well established by evidence/ opinion</p><ul id="l6"><li><p class="s36" style="padding-top: 2pt;padding-left: 17pt;text-indent: -9pt;text-align: left;">May be considered</p></li></ul></td></tr><tr style="height:105pt"><td style="width:36pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 4pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">COR III</p></td><td style="width:71pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">Meaning</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s36" style="padding-left: 8pt;text-indent: 0pt;text-align: left;">Suggested phrasing</p></td><td style="width:165pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 8pt;padding-right: 81pt;text-indent: 0pt;text-align: left;">No bene<span class="s37">ﬁ</span>t (bene<span class="s37">ﬁ</span>t <span class="s39">¼ </span>risk) Harm (risk <span class="s38">&gt; </span>bene<span class="s37">ﬁ</span>t)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s36" style="padding-left: 8pt;text-indent: 0pt;text-align: left;">Moderate</p><ul id="l7"><li><p class="s36" style="padding-top: 1pt;padding-left: 17pt;text-indent: -9pt;text-align: left;">Is not recommended</p></li><li><p class="s36" style="padding-left: 17pt;text-indent: -9pt;text-align: left;">Is not indicated/useful/effective/bene<span class="s37">ﬁ</span>cial</p></li><li><p class="s36" style="padding-left: 8pt;padding-right: 14pt;text-indent: 0pt;line-height: 108%;text-align: left;">Should not be performed/administered/other Strong</p></li><li><p class="s36" style="padding-left: 17pt;text-indent: -9pt;text-align: left;">Potentially harmful</p></li><li><p class="s36" style="padding-left: 17pt;text-indent: -9pt;text-align: left;">Causes harm</p></li><li><p class="s36" style="padding-left: 17pt;text-indent: -9pt;text-align: left;">Associated with excess morbidity/mortality</p></li><li><p class="s36" style="padding-left: 17pt;text-indent: -9pt;text-align: left;">Should not be performed/administered/other</p></li></ul></td><td style="width:152pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 18pt;padding-right: 7pt;text-indent: -9pt;line-height: 108%;text-align: left;">Evidence or general agreement that the given treatment or procedure is not useful/ effective, and in some cases may be harmful</p><ul id="l8"><li><p class="s36" style="padding-top: 2pt;padding-left: 17pt;text-indent: -9pt;text-align: left;">Is not recommended</p></li></ul></td></tr><tr style="height:21pt"><td style="width:424pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="4"><p class="s41" style="padding-top: 6pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">ACC <span class="s42">¼ </span>American College of Cardiology; AHA <span class="s42">¼ </span>American Heart Association; COR <span class="s42">¼ </span>Class of Recommendation; ESC <span class="s42">¼ </span>European Society of Cardiology.</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 41pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">ejection fraction <span class="s43">&lt;</span>30%, MI at presentation, vein graft PCI, and stent diameter <span class="s43">&lt;</span>3 mm. Conversely, it assigns negative integer values to older age categories. Based on the DAPT score, continued P2Y12 inhibitor use is</p><p style="padding-top: 2pt;padding-left: 41pt;text-indent: 0pt;line-height: 140%;text-align: justify;">expected to decrease ischemic events (without a substantial increase in bleeding) or to increase bleeding (without a substantial reduction in ischemic</p><p style="padding-left: 41pt;text-indent: 0pt;line-height: 10pt;text-align: justify;">events) in patients with <span class="s44">$</span>2 or <span class="s43">&lt;</span>2 points, respectively.</p><p style="padding-top: 1pt;padding-left: 41pt;text-indent: 0pt;line-height: 140%;text-align: justify;">With respect to speci<span class="s28">ﬁ</span>c bleeding risk prediction, the approach of the 2016 ACC/AHA update to risk strati- <span class="s28">ﬁ</span>cation is essentially qualitative, with a focus on bleeding risk factors rather than an emphasis on predictive models. After the publication of the 2016 ACC/AHA document, the PRECISE-DAPT (Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy) score has become available. The 2017 ESC update suggests using this 5-item bleeding risk score (age, creatinine clearance, hemoglobin, white blood</p><p style="padding-top: 5pt;padding-left: 9pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a href="#bookmark44" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">cell count, and prior spontaneous bleeding) for the prediction of out-of-hospital bleeding hazard as a complementary tool to the DAPT score </a><span style=" color: #007FAC;">(11)</span>. In particular, the ESC guideline suggests the use of risk scores designed to evaluate the bene<span class="s28">ﬁ</span>ts and risks of different DAPT duration (i.e., PRECISE-DAPT and DAPT scores) with a COR IIb, LOE A.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s32" style="padding-left: 9pt;text-indent: 0pt;text-align: justify;">TYPE OF P2Y12 INHIBITOR AND TIME OF INITIATION.</p><p class="s9" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 139%;text-align: justify;"><a href="#bookmark29" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">Recommendations on P2Y12 inhibitor selection and timing are largely consistent between the ACC/AHA and ESC updates, and depend on the clinical scenario (</a><span class="s30">Figures 1 to 3</span><a href="#bookmark39" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">) </a>(6,7)<a href="#bookmark45" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">. Both documents recommend that in patients with NSTE-ACS or STEMI with no contraindications, aspirin therapy should be com- bined with ticagrelor or prasugrel in preference to clopidogrel. However, with the same LOE B (based on data from 2 large randomized trials) </a>(12,13)<span style=" color: #000;">, in the 2017 ESC update, prasugrel or ticagrelor are given</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse" cellspacing="0"><tr style="height:28pt"><td style="width:278pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DEE9F7"><p class="s33" style="padding-top: 4pt;padding-left: 5pt;padding-right: 14pt;text-indent: 0pt;line-height: 131%;text-align: left;">TABLE 2 <span class="s34">Comparative Meaning and Suggested Phrasing of Levels of Evidence in the ACC/AHA and ESC Guidelines</span></p></td></tr><tr style="height:13pt"><td style="width:178pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s35" style="padding-top: 3pt;padding-left: 89pt;padding-right: 62pt;text-indent: 0pt;text-align: center;">ACC/AHA</p></td><td style="width:100pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s35" style="padding-top: 3pt;padding-left: 43pt;padding-right: 44pt;text-indent: 0pt;text-align: center;">ESC</p></td></tr><tr style="height:35pt"><td style="width:178pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt" bgcolor="#DEE9F7"><p class="s36" style="padding-right: 34pt;text-indent: 0pt;line-height: 9pt;text-align: right;">LOE A <span class="s45">• </span>High-quality evidence from <span class="s38">&gt;</span>1 RCT</p><ul id="l9"><li><p class="s36" style="padding-left: 40pt;padding-right: 33pt;text-indent: -40pt;line-height: 7pt;text-align: right;">Meta-analyses of high-quality RCTs</p></li><li><p class="s40" style="padding-left: 40pt;padding-right: 3pt;text-indent: -9pt;line-height: 8pt;text-align: left;">$<span class="s36">1 RCTs corroborated by high-quality registry studies</span></p></li></ul></td><td style="width:100pt;border-top-style:solid;border-top-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DEE9F7"><ul id="l10"><li><p class="s36" style="padding-top: 1pt;padding-left: 13pt;padding-right: 5pt;text-indent: -9pt;line-height: 108%;text-align: justify;">Data derived from multiple randomized clinical trials or meta-analyses</p></li></ul></td></tr><tr style="height:77pt"><td style="width:178pt;border-left-style:solid;border-left-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">LOE B Randomized (R)</p><ul id="l11"><li><p class="s36" style="padding-left: 40pt;text-indent: -9pt;text-align: left;">Moderate-quality evidence from <span class="s40">$</span>1 RCTs</p></li><li><p class="s36" style="padding-left: 40pt;text-indent: -9pt;text-align: left;">Meta-analyses of moderate-quality RCTs</p><p class="s36" style="padding-top: 3pt;padding-left: 30pt;text-indent: 0pt;text-align: left;">Nonrandomized (NR)</p></li><li><p class="s36" style="padding-left: 40pt;text-indent: -9pt;text-align: left;">Moderate-quality evidence from <span class="s40">$</span>1</p><p class="s36" style="padding-left: 40pt;padding-right: 3pt;text-indent: 0pt;line-height: 108%;text-align: left;">well-designed, well-executed nonrandomized studies, observational studies, or registry studies</p></li><li><p class="s36" style="padding-left: 40pt;text-indent: -9pt;text-align: left;">Meta-analyses of such studies</p></li></ul></td><td style="width:100pt;border-right-style:solid;border-right-width:1pt"><ul id="l12"><li><p class="s36" style="padding-top: 1pt;padding-left: 13pt;padding-right: 5pt;text-indent: -9pt;line-height: 108%;text-align: justify;">Data derived from a single randomized clinical trial or large nonrandomized study</p></li></ul></td></tr><tr style="height:89pt"><td style="width:178pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt" bgcolor="#DEE9F7"><p class="s36" style="padding-top: 1pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">LOE C Limited data (LD)</p><ul id="l13"><li><p class="s36" style="padding-left: 40pt;padding-right: 3pt;text-indent: -9pt;line-height: 108%;text-align: justify;">Randomized or nonrandomized observational or registry studies with limitation of design or execution</p></li><li><p class="s36" style="padding-left: 40pt;text-indent: -9pt;text-align: left;">Meta-analyses of such studies</p></li><li><p class="s36" style="padding-left: 40pt;padding-right: 3pt;text-indent: -9pt;line-height: 108%;text-align: justify;">Physiological or mechanistic studies in human subjects</p><p class="s36" style="padding-top: 2pt;padding-left: 30pt;text-indent: 0pt;text-align: left;">Expert opinion (EO)</p></li><li><p class="s36" style="padding-top: 1pt;padding-left: 40pt;padding-right: 3pt;text-indent: -9pt;line-height: 109%;text-align: justify;">Consensus of expert opinion based on clinical experience</p></li></ul></td><td style="width:100pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DEE9F7"><ul id="l14"><li><p class="s36" style="padding-top: 1pt;padding-left: 13pt;padding-right: 5pt;text-indent: -9pt;line-height: 108%;text-align: left;">Consensus of opinion of the experts and/or small studies, retrospective studies, registries</p></li></ul></td></tr><tr style="height:21pt"><td style="width:278pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s41" style="padding-top: 6pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">LOE <span class="s42">¼ </span>Level of Evidence; RCT <span class="s42">¼ </span><a href="#bookmark27" style=" color: black; font-family:&quot;Century Gothic&quot;, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 5pt;">randomized clinical trial; other abbreviations as in </a><span style=" color: #007FAC; font-family:Tahoma, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 5pt;">Table 1</span>.</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"/><p class="s9" style="padding-top: 5pt;padding-left: 327pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a href="#bookmark46" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;" name="bookmark4">were administered across trials. Recommendations for STEMI patients in the 2017 ESC update are similar to those previously mentioned for NSTE-ACS pa- tients, with the exception that prasugrel can be given before coronary angiography if the indication to pri- mary PCI is established, because this strategy was permitted in the regulatory trial of prasugrel and not shown to be harmful </a>(13)<a href="#bookmark51" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">. Patients undergoing thrombolysis were excluded from the regulatory trials of ticagrelor and prasugrel and therefore are currently recommended to receive clopidogrel by the ESC (COR I, LOE A). The ESC guidelines for STEMI, published simultaneously with the 2017 DAPT focused update, provide  consistent messages  and recommendations </a>(19)<span style=" color: #000;">. The 2017 ESC focused update also provide in- dications regarding DAPT for patients with stable CAD undergoing PCI, where clopidogrel is the drug of choice (COR I, LOE A), with pre-treatment applicable if the probability of PCI is high (COR IIb, LOE C). Prasugrel and ticagrelor may be considered in selected patients who are at high ischemic risk and low bleeding risk (COR IIb, LOE C).</span><a name="bookmark5">&zwnj;</a><a name="bookmark28">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 109pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a href="#bookmark39" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">COR I, with clopidogrel reserved for those who cannot receive prasugrel or ticagrelor, whereas in the 2016 ACC/AHA update, there is a preferential COR IIa in favor of prasugrel or ticagrelor over clopidogrel </a><span style=" color: #007FAC;">(6,7)</span>. With respect to the issue of pre-treatment with P2Y12 inhibitors, the 2016 ACC/AHA update refers to previ- ous guidelines, where a loading dose was recom- mended (COR I, LOE A) <span class="s11">“</span>before the procedure<span class="s11">” </span>in NSTE-ACS patients undergoing PCI with stenting</p><p class="s9" style="padding-left: 109pt;text-indent: 0pt;line-height: 140%;text-align: justify;">(14) <span style=" color: #000;">and </span><span class="s11">“</span><span style=" color: #000;">as early as possible</span><span class="s11">” </span><a href="#bookmark48" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">or at the time of pri- mary PCI in STEMI patients (COR I, LOE B) </a>(15)<span style=" color: #000;">. The topic is covered in greater detail by the 2017 ESC update, where the indication for pre-treatment is speci</span><span class="s28">ﬁ</span><a href="#bookmark49" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">c to the P2Y12 inhibitor and the clinical setting. Accordingly, in NSTE-ACS, ticagrelor and clopidogrel (where applicable) should be considered early (COR IIa, LOE C) regardless of the initial management strategy (e.g., invasive or conservative), whereas prasugrel is recommended only for patients under- going PCI where the coronary anatomy is known (otherwise the COR is III, LOE B, based on trial data</a> [16]<a href="#bookmark50" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">). Notably, in previous ESC guidelines for NSTE- ACS, no recommendation for or against pre- treatment with ticagrelor or clopidogrel was formu- lated due to lack of adequate investigations on the subject </a>(17,18)<span style=" color: #000;">. Still, in the absence of clear data and acknowledging the limitations of this approach, the ESC 2017 task force aimed to provide practical guid- ance to physicians on the matter by leveraging the timing by which ticagrelor, prasugrel, and clopidogrel</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s32" style="padding-left: 9pt;text-indent: 0pt;text-align: justify;">PLATELET FUNCTION TESTING AND GENETIC</p><p style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><span class="s32">TESTING. </span><a href="#bookmark52" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">Routine platelet function testing to adjust antiplatelet therapy before or after elective stenting is not recommended by the ACC/AHA or ESC due to the neutral results of multiple randomized trials </a><a href="#bookmark52" class="s8">(20</a><a href="#bookmark52" class="s14">–</a><span style=" color: #007FAC;">23)</span>. A reduced platelet inhibition of clopidogrel was re- ported in subjects who are poor metabolizers of the drug (e.g., due to 2 loss-of-function alleles of the <span class="s47">CYP2C19 </span>gene), and a consistent drug safety <span class="s11">“</span>boxed warning<span class="s11">” </span><a href="#bookmark53" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">was issued by the Food and Drug Adminis- tration </a><span style=" color: #007FAC;">(24,25)</span><a href="#bookmark41" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">. However, according to the new 2018 ESC guidelines for myocardial revascularization, de- escalation of P2Y12 inhibitors (e.g., from prasugrel to clopidogrel in patients with normal clopidogrel platelet inhibition response) guided by platelet function testing may be considered, particularly in ACS unsuitable for 12-month DAPT (COR IIb, LOE B) </a><span style=" color: #007FAC;">(8)</span>. This recommendation follows the result of the TROPICAL ACS (Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes) trial, published after the release of the 2017 ESC focused update on DAPT, where genetic testing is not currently recommended to guide DAPT. A new study reported after publica- tion of the ACC/AHA and ESC updates may suggest a need to update this topic, as described in the following text.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s32" style="padding-left: 9pt;text-indent: 0pt;text-align: justify;">SWITCHING OF P2Y12 INHIBITORS. <span class="p">The issue of</span></p><p style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 140%;text-align: justify;">switching is simply referred to but not addressed by the 2016 ACC/AHA update by acknowledging the lack</p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:41.964pt" cellspacing="0"><tr style="height:27pt"><td style="width:496pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="4" bgcolor="#DEE9F7"><p class="s33" style="padding-top: 5pt;padding-left: 11pt;padding-right: 41pt;text-indent: 0pt;line-height: 131%;text-align: left;"><a name="bookmark6">FIGURE 1 </a><span class="s34">Decision-Making for the Selection of the P2Y12 Inhibitors in DAPT Combination With Aspirin for Patients With NSTE-ACS According to the ACC/AHA and ESC Guidelines</span><a name="bookmark29">&zwnj;</a></p></td></tr><tr style="height:280pt"><td style="width:158pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s48" style="padding-top: 5pt;padding-left: 80pt;padding-right: 58pt;text-indent: 0pt;text-align: center;">CABG</p></td><td style="width:138pt;border-bottom-style:solid;border-bottom-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s48" style="padding-left: 59pt;padding-right: 17pt;text-indent: 0pt;text-align: center;">Invasive management</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s48" style="padding-left: 59pt;padding-right: 17pt;text-indent: 0pt;text-align: center;">Coronary angiography</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s48" style="padding-left: 59pt;padding-right: 17pt;text-indent: 0pt;text-align: center;">PCI</p></td><td style="width:60pt;border-bottom-style:solid;border-bottom-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s48" style="padding-left: 18pt;text-indent: 0pt;text-align: left;">NSTE-ACS</p></td><td style="width:140pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s48" style="padding-left: 14pt;padding-right: 51pt;text-indent: 0pt;text-align: center;">Conservative management</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s48" style="padding-left: 14pt;padding-right: 48pt;text-indent: 0pt;text-align: center;">Medical therapy</p></td></tr><tr style="height:66pt"><td style="width:496pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="4"><p class="s36" style="padding-top: 7pt;padding-left: 11pt;padding-right: 14pt;text-indent: 0pt;line-height: 135%;text-align: left;"><span class="s49">*</span>According to the 2017 ESC focused update, pre-treatment with a P2Y12 inhibitor is <span class="s39">“</span>generally recommended in patients in whom coronary anatomy is known and the decision to proceed to PCI is made.<span class="s39">” </span>A COR IIa is given in patients with NSTE-ACS undergoing invasive management, where ticagrelor administration, or clopidogrel if ticagrelor is not an option, should be considered <span class="s39">“</span>as soon as the diagnosis is established.<span class="s39">” </span>ACC <span class="s39">¼ </span>American College of Cardiology; AHA <span class="s39">¼ </span>American Heart Association; COR <span class="s39">¼ </span>Class of Recommendation; DAPT <span class="s39">¼ </span>dual antiplatelet therapy; ESC <span class="s39">¼ </span>European Society of Cardiology; LOE = Level of Evidence; NSTE-ACS <span class="s39">¼ </span>non<span class="s39">–</span>ST-segment elevation acute coronary syndrome; TIA <span class="s39">¼ </span>transient ischemic attack.</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="628" height="229" alt="image" src="j.jacc.2018.09.057/Image_009.png"/></span></p><table style="border-collapse:collapse" cellspacing="0"><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" rowspan="2" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:39pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="2" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">ACC/AHA</p></td><td style="width:39pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="2" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 12pt;padding-right: 11pt;text-indent: 0pt;text-align: center;">ESC</p></td></tr><tr style="height:9pt"><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">COR</p></td><td style="width:39pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="2"><p class="s48" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">LOE COR</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">LOE</p></td></tr><tr style="height:9pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Ticagrelor pre-treatment</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#FDC059"><p class="s48" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">IIa</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="text-indent: 0pt;text-align: center;">C</p></td></tr><tr style="height:9pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Clopidogrel pre-treatment</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#FDC059"><p class="s48" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">IIa</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="text-indent: 0pt;text-align: center;">C</p></td></tr><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Prasugrel pre-treatment</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#F15F48"><p class="s50" style="padding-left: 7pt;text-indent: 0pt;text-align: left;">III</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5D7792"><p class="s50" style="text-indent: 0pt;text-align: center;">B</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse" cellspacing="0"><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" rowspan="2" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:39pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="2" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">ACC/AHA</p></td><td style="width:39pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="2" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 11pt;padding-right: 11pt;text-indent: 0pt;text-align: center;">ESC</p></td></tr><tr style="height:9pt"><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">COR</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">LOE</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-right: 3pt;text-indent: 0pt;text-align: right;">COR</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">LOE</p></td></tr><tr style="height:9pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Heart Team management</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="text-indent: 0pt;text-align: center;">C</p></td></tr><tr style="height:9pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Continue aspirin</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="text-indent: 0pt;text-align: center;">C</p></td></tr><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Discontinue P2Y<span class="s51">12</span></p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#FDC059"><p class="s48" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">IIa</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5D7792"><p class="s50" style="text-indent: 0pt;text-align: center;">B</p></td></tr><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Resume P2Y<span class="s51">12 </span>early</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="text-indent: 0pt;text-align: center;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">C-L</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="text-indent: 0pt;text-align: center;">C</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse" cellspacing="0"><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" rowspan="2" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:39pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="2" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">ACC/AHA</p></td><td style="width:39pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="2" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 12pt;padding-right: 11pt;text-indent: 0pt;text-align: center;">ESC</p></td></tr><tr style="height:9pt"><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-right: 3pt;text-indent: 0pt;text-align: right;">COR</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">LOE</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">COR</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">LOE</p></td></tr><tr style="height:9pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;line-height: 7pt;text-align: left;">P2Y<span class="s51">12 </span>pre-treatment*</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="text-indent: 0pt;text-align: center;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5D7792"><p class="s50" style="text-indent: 0pt;text-align: center;">A</p></td></tr><tr style="height:9pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Ticagrelor</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="text-indent: 0pt;text-align: center;">B</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="text-indent: 0pt;text-align: center;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="text-indent: 0pt;text-align: center;">B</p></td></tr><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">Preferred to clopidogrel</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#FDC059"><p class="s48" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">IIa</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">B-R</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Prasugrel</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="text-indent: 0pt;text-align: center;">B</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="text-indent: 0pt;text-align: center;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="text-indent: 0pt;text-align: center;">B</p></td></tr><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">Preferred to clopidogrel</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#FDC059"><p class="s48" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">IIa</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">B-R</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-right: 4pt;text-indent: 0pt;text-align: right;">History of stroke or TIA</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#F15F48"><p class="s50" style="padding-right: 6pt;text-indent: 0pt;text-align: right;">III</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">B-R</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Clopidogrel</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="text-indent: 0pt;text-align: center;">B</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="text-indent: 0pt;text-align: center;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5D7792"><p class="s50" style="text-indent: 0pt;text-align: center;">A</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse" cellspacing="0"><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" rowspan="2" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:39pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="2" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">ACC/AHA</p></td><td style="width:39pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="2" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 12pt;padding-right: 11pt;text-indent: 0pt;text-align: center;">ESC</p></td></tr><tr style="height:9pt"><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-right: 3pt;text-indent: 0pt;text-align: right;">COR</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-right: 3pt;text-indent: 0pt;text-align: right;">LOE</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">COR</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">LOE</p></td></tr><tr style="height:9pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Ticagrelor</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="padding-right: 7pt;text-indent: 0pt;text-align: right;">B</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="text-indent: 0pt;text-align: center;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="text-indent: 0pt;text-align: center;">B</p></td></tr><tr style="height:9pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">Preferred to clopidogrel</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#FDC059"><p class="s48" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">IIa</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="padding-right: 4pt;text-indent: 0pt;text-align: right;">B-R</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="text-indent: 0pt;text-align: center;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="text-indent: 0pt;text-align: center;">B</p></td></tr><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Prasugrel</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#F15F48"><p class="s50" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">III</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="text-indent: 0pt;text-align: center;">B</p></td></tr><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-right: 4pt;text-indent: 0pt;text-align: right;">History of stroke or TIA</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#F15F48"><p class="s50" style="padding-right: 6pt;text-indent: 0pt;text-align: right;">III</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="padding-right: 4pt;text-indent: 0pt;text-align: right;">B-R</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Clopidogrel</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="padding-right: 7pt;text-indent: 0pt;text-align: right;">B</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"/><p class="s9" style="padding-top: 5pt;padding-left: 41pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><span style=" color: #000;">of randomized studies on the long-term safety and ef</span><span class="s28">ﬁ</span><a href="#bookmark39" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">cacy of transitioning from one P2Y12 inhibitor to another </a>(6)<a href="#bookmark54" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">. In the 2017 ESC update the topic is covered in greater detail, and 2 CORs are issued: 1 for the early upgrading from clopidogrel to ticagrelor in ACS (COR I, LOE B), as permitted in the PLATO (Platelet inhibition and patient outcomes) trial of ticagrelor </a>(26)<a href="#bookmark40" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">; and 1 for switching between P2Y12 in- hibitors if side-effects or drug intolerance occur (COR IIb, LOE C) </a>(7)<span style=" color: #000;">. A practical algorithm for switching between oral P2Y12 inhibitors in the acute and chronic setting is also provided in the 2017 ESC update, which depicts 2 scenarios. In the </span><span class="s28">ﬁ</span><span style=" color: #000;">rst scenario (switching in the acute setting), a reload is always recommended to avoid gaps in the inhibitory effects of any of the P2Y12 inhibitors. Switching to prasugrel or ticagrelor can occur irrespective of prior clopidogrel dosing and timing, whereas downgrades to clopidogrel should occur at 24 h from the last prasugrel or ticagrelor dose. Transitions between prasugrel and ticagrelor should also occur at 24 h from the last prasugrel or</span></p><p style="padding-top: 5pt;padding-left: 9pt;text-indent: 0pt;line-height: 140%;text-align: justify;">ticagrelor dose. In the second scenario (switch in the chronic setting) a reload is not always necessary, depending on the switched drugs (e.g., a loading dose is recommended when transitioning from ticagrelor to prasugrel or from ticagrelor to clopidogrel to avoid drug-to-drug interactions limiting the antiplatelet effect of ticagrelor, as noted in pharmacodynamic investigations in the <span class="s28">ﬁ</span><a href="#bookmark55" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">eld). All of these practices are in line with recently available expert consensus rec- ommendations, as noted in the following text </a><span style=" color: #007FAC;">(27,28)</span>.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s32" style="padding-left: 9pt;text-indent: 0pt;text-align: justify;">PROTON PUMP INHIBITORS AND DAPT. <span class="p">In 2009, the</span></p><p class="s9" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a href="#bookmark56" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">U.S. Food and Drug Administration issued a warning that omeprazole reduces the antithrombotic effect of clopidogrel when taken concomitantly </a>(29,30)<span style=" color: #000;">. The writing committee of the 2016 ACC/AHA update felt that although a pharmacokinetic interaction exists between omeprazole and clopidogrel, there is no ev- idence of diminished clinical ef</span><span class="s28">ﬁ</span><a href="#bookmark57" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">cacy </a>(31)<span style=" color: #000;">. Therefore, among measures to minimize bleeding while on DAPT, the 2016 ACC/AHA update recommends the use</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:38.166pt" cellspacing="0"><tr style="height:27pt"><td style="width:496pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="4" bgcolor="#DEE9F7"><p class="s33" style="padding-top: 5pt;padding-left: 11pt;padding-right: 51pt;text-indent: 0pt;line-height: 131%;text-align: left;"><a name="bookmark7">FIGURE 2 </a><span class="s34">Decision-Making for the Selection of the P2Y12 Inhibitors in DAPT Combination With Aspirin for Patients With STEMI According to the ACC/AHA and ESC Guidelines</span><a name="bookmark8">&zwnj;</a></p></td></tr><tr style="height:280pt"><td style="width:158pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s48" style="padding-top: 5pt;padding-left: 80pt;padding-right: 58pt;text-indent: 0pt;text-align: center;">CABG</p></td><td style="width:140pt;border-bottom-style:solid;border-bottom-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s48" style="padding-left: 59pt;padding-right: 19pt;text-indent: 0pt;text-align: center;">Primary PCI</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s48" style="padding-left: 59pt;padding-right: 19pt;text-indent: 0pt;text-align: center;">Coronary angiography</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s48" style="padding-left: 59pt;padding-right: 19pt;text-indent: 0pt;text-align: center;">PCI</p></td><td style="width:64pt;border-bottom-style:solid;border-bottom-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s48" style="padding-left: 20pt;text-indent: 0pt;text-align: left;">STEMI</p></td><td style="width:134pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s48" style="padding-left: 30pt;text-indent: 0pt;text-align: left;">Fibrinolysis</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s48" style="padding-left: 25pt;text-indent: 0pt;text-align: left;">Medical therapy</p></td></tr><tr style="height:26pt"><td style="width:496pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="4"><p class="s36" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">STEMI <span class="s39">¼ </span><a href="#bookmark29" style=" color: black; font-family:&quot;Century Gothic&quot;, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt;">ST-segment elevation myocardial infarction; other abbreviations as in </a><span class="s83">Figure 1</span>.</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="628" height="229" alt="image" src="j.jacc.2018.09.057/Image_010.png"/></span></p><table style="border-collapse:collapse" cellspacing="0"><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" rowspan="2" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:39pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="2" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">ACC/AHA</p></td><td style="width:39pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="2" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 11pt;padding-right: 11pt;text-indent: 0pt;text-align: center;">ESC</p></td></tr><tr style="height:9pt"><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">COR</p></td><td style="width:39pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="2"><p class="s48" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">LOE COR</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">LOE</p></td></tr><tr style="height:9pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;line-height: 7pt;text-align: left;">P2Y<span class="s51">12 </span>pre-treatment</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="text-indent: 0pt;text-align: center;">I</p></td><td style="width:19pt;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F"><p class="s50" style="text-indent: 0pt;text-align: center;">B</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="padding-left: 8pt;text-indent: 0pt;text-align: left;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5D7792"><p class="s50" style="text-indent: 0pt;text-align: center;">A</p></td></tr><tr style="height:9pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Ticagrelor</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="padding-left: 8pt;text-indent: 0pt;text-align: left;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="text-indent: 0pt;text-align: center;">B</p></td></tr><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Prasugrel</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="padding-left: 8pt;text-indent: 0pt;text-align: left;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="text-indent: 0pt;text-align: center;">B</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse" cellspacing="0"><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" rowspan="2" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:39pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="2" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">ACC/AHA</p></td><td style="width:39pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="2" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 11pt;padding-right: 11pt;text-indent: 0pt;text-align: center;">ESC</p></td></tr><tr style="height:9pt"><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">COR</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">LOE</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">COR</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">LOE</p></td></tr><tr style="height:9pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Ticagrelor</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="text-indent: 0pt;text-align: center;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="text-indent: 0pt;text-align: center;">B</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="text-indent: 0pt;text-align: center;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="text-indent: 0pt;text-align: center;">B</p></td></tr><tr style="height:9pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">Preferred to clopidogrel</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#FDC059"><p class="s50" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">IIa</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">B-R</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Prasugrel</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="text-indent: 0pt;text-align: center;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="text-indent: 0pt;text-align: center;">B</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="text-indent: 0pt;text-align: center;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="text-indent: 0pt;text-align: center;">B</p></td></tr><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">Preferred to clopidogrel</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#FDC059"><p class="s50" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">IIa</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">B-R</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-right: 4pt;text-indent: 0pt;text-align: right;">History of stroke or TIA</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#F15F48"><p class="s50" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">III</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">B-R</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Clopidogrel</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="text-indent: 0pt;text-align: center;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="text-indent: 0pt;text-align: center;">B</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="text-indent: 0pt;text-align: center;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5D7792"><p class="s50" style="text-indent: 0pt;text-align: center;">A</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"/><p class="s9" style="padding-left: 109pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><span style=" color: #000;">of proton pump inhibitors in patients with a history of gastrointestinal bleeding (COR I) and those at increased risk of gastrointestinal bleeding, including the elderly and patients with concomitant use of warfarin, steroids, or nonsteroidal anti-in</span><span class="s28">ﬂ</span><a href="#bookmark39" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">ammatory drugs (COR IIa); however, the routine use of proton pump inhibitors for patients at low risk of gastroin- testinal bleeding is not recommended (COR III) </a>(6)<span style=" color: #000;">. The 2016 ACC/AHA update does not mention LOE for these recommendations, which were </span><span class="s11">“</span><span style=" color: #000;">C</span><span class="s11">” </span><a href="#bookmark58" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">in previous guideline for PCI </a>(32)<a href="#bookmark40" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">. Conversely, in the ESC docu- ment, the use of a proton pump inhibitor while on DAPT is COR I, LOE B, with no further distinctions </a>(7) <a href="#bookmark57" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">based on an in-depth assessment of patient selection criteria and results of a large trial </a>(31)<span style=" color: #000;">.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s31" style="padding-left: 109pt;text-indent: 0pt;text-align: justify;">RECOMMENDATIONS ON DAPT DURATION</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 109pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="272" height="0" alt="image" src="j.jacc.2018.09.057/Image_011.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 109pt;text-indent: 0pt;line-height: 138%;text-align: justify;"><a href="#bookmark39" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">Recommendations on DAPT duration play a major part in the ACC/AHA and ESC focused updates and are discussed in the following paragraphs </a><span style=" color: #007FAC;">(6,7)</span>. For each clinical scenario, an evidence summary is provided, followed by a description of speci<span class="s28">ﬁ</span><a href="#bookmark30" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">c recommenda- tions (</a><a href="#bookmark33" class="s29">Central Illustration, </a><span class="s30">Figure 4</span>).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse" cellspacing="0"><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" rowspan="2" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:39pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="2" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">ACC/AHA</p></td><td style="width:39pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="2" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 12pt;padding-right: 11pt;text-indent: 0pt;text-align: center;">ESC</p></td></tr><tr style="height:9pt"><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">COR</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">LOE</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-right: 3pt;text-indent: 0pt;text-align: right;">COR</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">LOE</p></td></tr><tr style="height:9pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Heart Team management</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="text-indent: 0pt;text-align: center;">C</p></td></tr><tr style="height:9pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Continue aspirin</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="text-indent: 0pt;text-align: center;">C</p></td></tr><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Discontinue P2Y<span class="s51">12</span></p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#FDC059"><p class="s48" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">IIa</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5D7792"><p class="s50" style="text-indent: 0pt;text-align: center;">B</p></td></tr><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Resume P2Y<span class="s51">12 </span>early</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="text-indent: 0pt;text-align: center;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">C-L</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="text-indent: 0pt;text-align: center;">C</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse" cellspacing="0"><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" rowspan="2" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:39pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="2" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">ACC/AHA</p></td><td style="width:39pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="2" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 11pt;padding-right: 11pt;text-indent: 0pt;text-align: center;">ESC</p></td></tr><tr style="height:9pt"><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-right: 3pt;text-indent: 0pt;text-align: right;">COR</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-right: 3pt;text-indent: 0pt;text-align: right;">LOE</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">COR</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">LOE</p></td></tr><tr style="height:9pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Ticagrelor</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="padding-right: 7pt;text-indent: 0pt;text-align: right;">B</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="text-indent: 0pt;text-align: center;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="padding-left: 7pt;text-indent: 0pt;text-align: left;">B</p></td></tr><tr style="height:9pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">Preferred to clopidogrel</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#FDC059"><p class="s50" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">IIa</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="padding-right: 4pt;text-indent: 0pt;text-align: right;">B-R</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="text-indent: 0pt;text-align: center;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="padding-left: 7pt;text-indent: 0pt;text-align: left;">B</p></td></tr><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">After thrombolysis</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="padding-right: 4pt;text-indent: 0pt;text-align: right;">B-R</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Prasugrel</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#F15F48"><p class="s50" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">III</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="padding-left: 7pt;text-indent: 0pt;text-align: left;">B</p></td></tr><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-right: 4pt;text-indent: 0pt;text-align: right;">History of stroke or TIA</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#F15F48"><p class="s50" style="padding-right: 6pt;text-indent: 0pt;text-align: right;">III</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="padding-right: 4pt;text-indent: 0pt;text-align: right;">B-R</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Clopidogrel</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="padding-right: 7pt;text-indent: 0pt;text-align: right;">B</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:10pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s48" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">After thrombolysis</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s50" style="padding-right: 4pt;text-indent: 0pt;text-align: right;">B-R</p></td><td style="width:20pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s50" style="text-indent: 0pt;text-align: center;">I</p></td><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5D7792"><p class="s50" style="padding-left: 7pt;text-indent: 0pt;text-align: left;">A</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"/><p class="s32" style="padding-left: 9pt;text-indent: 0pt;text-align: justify;">PATIENTS UNDERGOING PCI FOR STABLE CAD. <span class="p">The</span></p><p class="s9" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 139%;text-align: justify;"><a href="#bookmark59" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">current evidence base on DAPT duration for PCI pa- tients (mostly with stable CAD or low-risk ACS) is currently made of 8 studies of shorter (3 to 6 months) versus 12-month DAPT duration </a><a href="#bookmark59" class="s8">(33</a><a href="#bookmark59" class="s14">–</a>40)<a href="#bookmark61" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">, 3 studies of shorter (6 months) versus 24-month DAPT duration </a><a href="#bookmark61" class="s8">(41</a><a href="#bookmark61" class="s14">–</a>43)<span style=" color: #000;">, and 4 studies of prolonged/extended</span></p><p style="padding-left: 9pt;text-indent: 0pt;line-height: 10pt;text-align: justify;">(<span class="s43">&gt;</span>12 months) DAPT duration versus 12-month DAPT</p><p class="s9" style="padding-top: 1pt;padding-left: 9pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a href="#bookmark42" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">duration </a><a href="#bookmark42" class="s8">(9,44</a><a href="#bookmark42" class="s14">–</a>46) <a href="#bookmark31" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">(</a><span class="s30">Table 3</span><a href="#bookmark42" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">). Of these 15 trials, 10 were designed around the hypothesis of shorter DAPT being noninferior to longer DAPT and 5 were designed around the hypothesis of one strategy being superior to the other. Of the noninferiority trials, all but one used an open-label design, most had lower- than-anticipated observed ischemic event rates determining a bias toward noninferiority, and 4 were stopped prematurely. Of the superiority trials, one was stopped prematurely and only the DAPT (Dual Antiplatelet Therapy Study) </a>(9) <span style=" color: #000;">was adequately powered for relatively rare endpoints (i.e., stent thrombosis), showing a reduction in stent thrombosis and spontaneous myocardial infarction, at the expense of increased bleeding with extended DAPT compared with shortened DAPT duration. Notably,</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="320" height="95" alt="image" src="j.jacc.2018.09.057/Image_012.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="322" height="44" alt="image" src="j.jacc.2018.09.057/Image_013.png"/></span></p><table style="border-collapse:collapse" cellspacing="0"><tr style="height:16pt"><td style="width:115pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" rowspan="2" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:63pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="2" bgcolor="#DBE7F6"><p class="s53" style="padding-top: 3pt;padding-left: 16pt;text-indent: 0pt;text-align: left;">ACC/AHA</p></td><td style="width:62pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="2" bgcolor="#DBE7F6"><p class="s53" style="padding-top: 3pt;padding-left: 22pt;padding-right: 22pt;text-indent: 0pt;text-align: center;">ESC</p></td></tr><tr style="height:16pt"><td style="width:31pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s53" style="padding-top: 3pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">COR</p></td><td style="width:32pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s53" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">LOE</p></td><td style="width:31pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s53" style="padding-top: 3pt;padding-right: 8pt;text-indent: 0pt;text-align: right;">COR</p></td><td style="width:31pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s53" style="padding-top: 3pt;padding-left: 7pt;padding-right: 7pt;text-indent: 0pt;text-align: center;">LOE</p></td></tr><tr style="height:16pt"><td style="width:115pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s53" style="padding-top: 3pt;padding-left: 1pt;text-indent: 0pt;text-align: left;">P2Y<span class="s54">12 </span>inhibitor if high chance of PCI</p></td><td style="width:31pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:32pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:31pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#FDC059"><p class="s53" style="padding-top: 3pt;padding-right: 10pt;text-indent: 0pt;text-align: right;">IIb</p></td><td style="width:31pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s53" style="padding-top: 3pt;text-indent: 0pt;text-align: center;">C</p></td></tr><tr style="height:12pt"><td style="width:120pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#919396" colspan="2"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:120pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#919396" colspan="3"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"/><p style="padding-top: 5pt;padding-left: 41pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a href="#bookmark39" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;" name="bookmark9">the ACC/AHA and ESC focused updates base their recommendation on most of the previously mentioned evidence, with the exception of a few trials unavailable at the time of publication </a><span style=" color: #007FAC;">(6,7)</span>. In the systematic review for the 2016 ACC/AHA update, which encompassed the 11 trials available at the time of publication and 33,051 patients treated with pre- dominantly newer-generation drug-eluting stents, the use of DAPT for 12 months, compared with use for 3 to 6 months, resulted in no signi<span class="s28">ﬁ</span>cant differences in the incidence of death (odds ratio [OR]: 1.17; 95% con<span class="s28">ﬁ</span>dence interval [CI]: 0.85 to 1.63), major hemor- rhage (OR: 1.65; 95% CI: 0.97 to 2.82), MI (OR: 0.87;</p><table style="border-collapse:collapse" cellspacing="0"><tr style="height:16pt"><td style="width:115pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" rowspan="2" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:63pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="2" bgcolor="#DBE7F6"><p class="s53" style="padding-top: 3pt;padding-left: 16pt;text-indent: 0pt;text-align: left;">ACC/AHA</p></td><td style="width:62pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="2" bgcolor="#DBE7F6"><p class="s53" style="padding-top: 3pt;padding-left: 22pt;padding-right: 22pt;text-indent: 0pt;text-align: center;">ESC</p></td></tr><tr style="height:16pt"><td style="width:31pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s53" style="padding-top: 3pt;padding-left: 6pt;padding-right: 6pt;text-indent: 0pt;text-align: center;">COR</p></td><td style="width:32pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s53" style="padding-top: 3pt;padding-left: 6pt;padding-right: 6pt;text-indent: 0pt;text-align: center;">LOE</p></td><td style="width:31pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s53" style="padding-top: 3pt;padding-right: 8pt;text-indent: 0pt;text-align: right;">COR</p></td><td style="width:31pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s53" style="padding-top: 3pt;padding-left: 7pt;padding-right: 7pt;text-indent: 0pt;text-align: center;">LOE</p></td></tr><tr style="height:15pt"><td style="width:115pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s53" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">P2Y<span class="s54">12 </span>inhibitor</p></td><td style="width:31pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s55" style="padding-top: 3pt;text-indent: 0pt;text-align: center;">I</p></td><td style="width:32pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5D7792"><p class="s55" style="padding-top: 3pt;text-indent: 0pt;text-align: center;">A</p></td><td style="width:31pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:31pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:15pt"><td style="width:115pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s53" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Clopidogrel</p></td><td style="width:31pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s55" style="padding-top: 3pt;text-indent: 0pt;text-align: center;">I</p></td><td style="width:32pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#8595AB"><p class="s55" style="padding-top: 3pt;text-indent: 0pt;text-align: center;">B</p></td><td style="width:31pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#62B372"><p class="s55" style="padding-top: 3pt;text-indent: 0pt;text-align: center;">I</p></td><td style="width:31pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5D7792"><p class="s55" style="padding-top: 3pt;text-indent: 0pt;text-align: center;">A</p></td></tr><tr style="height:15pt"><td style="width:115pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s53" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Ticagrelor</p></td><td style="width:31pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:32pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:31pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#FDC059"><p class="s53" style="padding-top: 3pt;padding-right: 10pt;text-indent: 0pt;text-align: right;">IIb</p></td><td style="width:31pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s55" style="padding-top: 3pt;text-indent: 0pt;text-align: center;">C</p></td></tr><tr style="height:15pt"><td style="width:115pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p class="s53" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Prasugrel</p></td><td style="width:31pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:32pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#DBE7F6"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:31pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#FDC059"><p class="s53" style="padding-top: 3pt;padding-right: 10pt;text-indent: 0pt;text-align: right;">IIb</p></td><td style="width:31pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#5CA5DB"><p class="s55" style="padding-top: 3pt;text-indent: 0pt;text-align: center;">C</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"/><p class="s9" style="padding-left: 41pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a href="#bookmark62" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">95% CI: 0.65 to 1.18), or stent thrombosis (OR: 0.87; 95% CI: 0.49 to 1.55) </a>(47)<span style=" color: #000;">. Conversely, the use of DAPT for 18 to 48 months, compared with use for 6 to 12 months, was associated with no difference in all- cause death (OR: 1.14; 95% CI: 0.92 to 1.42) but was associated with increased major hemorrhage (OR: 1.58; 95% CI: 1.20 to 2.09), decreased MI (OR: 0.67;</span></p><p style="padding-left: 41pt;text-indent: 0pt;text-align: justify;">95% CI: 0.47 to 0.95), and decreased stent thrombosis</p><p class="s9" style="padding-top: 3pt;padding-left: 41pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a href="#bookmark63" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">(OR: 0.45; 95% CI: 0.24 to 0.74). Three overlapping meta-analyses encompassing 10 randomized trials of DAPT duration showed similar results and were referenced to substantiate the 2017 ESC update, which does not include a systematic review like the 2016 ACC/AHA update </a><a href="#bookmark63" class="s8">(48</a><a href="#bookmark63" class="s14">–</a>50)<span style=" color: #000;">.</span></p><p style="padding-left: 41pt;text-indent: 9pt;line-height: 140%;text-align: justify;">With regard to speci<span class="s28">ﬁ</span>c recommendations, in pa- tients with stable CAD undergoing PCI the 2016 ACC/ AHA update recommends aspirin inde<span class="s28">ﬁ</span><a href="#bookmark39" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">nitely (COR I, LOE B) and clopidogrel for 1 month after implantation of a bare-metal stent (COR I, LOE A) or 6 months after implantation of a drug-eluting stent (COR I, LOE B) </a><span style=" color: #007FAC;">(6)</span>. Patients who tolerate DAPT during this manda- tory course without a bleeding complication and who are not at high risk of bleeding are candidates for an unde<span class="s28">ﬁ</span>ned period of prolonged DAPT (COR IIb, LOE A). Conversely, patients treated with drug-eluting stents who are at high risk of bleeding or develop signi<span class="s28">ﬁ</span><a href="#bookmark40" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">- cant overt bleeding may discontinue DAPT at 3 months (COR IIb, LOE C). In the 2017 ESC update, DAPT is recommended for 6 months irrespective of the stent type (COR I, LOE A), with drug-eluting stents representing the preferred treatment option (COR I, LOE  A) </a><span style=" color: #007FAC;">(7)</span>. Similarly, patients who receive treatment with drug-coated balloons should receive DAPT for 6 months (COR IIa, LOE B). In all PCI pa- tients with  stable CAD, DAPT  prolongation beyond 6 months and up to 30 months may be considered in patients who have tolerated DAPT and are at low bleeding risk but high thrombotic risk (COR IIb, LOE A), whereas patients who are at high bleeding risk are candidates for a shorter 3-month (COR IIa, LOE</p><ol id="l15"><ol id="l16"><li><p style="padding-left: 53pt;text-indent: -11pt;text-align: left;">or even 1-month (COR IIb, LOE C) term of DAPT.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:9.79112pt" cellspacing="0"><tr style="height:37pt"><td style="width:278pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DEE9F7"><p class="s33" style="padding-top: 5pt;padding-left: 11pt;padding-right: 14pt;text-indent: 0pt;line-height: 131%;text-align: left;">FIGURE 3 <span class="s34">Decision-Making for the Selection of the P2Y12 Inhibitors in DAPT Combi- nation With Aspirin for Patients With  Stable Coronary Artery Disease  Undergoing PCI According to the ACC/AHA and ESC Guidelines</span></p></td></tr><tr style="height:277pt"><td style="width:278pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s53" style="padding-left: 103pt;padding-right: 103pt;text-indent: 0pt;text-align: center;">Stable CAD</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s53" style="padding-left: 103pt;padding-right: 103pt;text-indent: 0pt;text-align: center;">Coronary angiography</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s53" style="padding-left: 103pt;padding-right: 103pt;text-indent: 0pt;text-align: center;">PCI</p></td></tr><tr style="height:26pt"><td style="width:278pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s83" style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><a href="#bookmark29" style=" color: black; font-family:&quot;Century Gothic&quot;, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt;">Abbreviations as in </a>Figure 1<span class="s36">.</span></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 9pt;text-indent: 0pt;line-height: 140%;text-align: justify;">In aggregate, a consistent message of both guide- lines is a shift toward a shorter standard post-PCI DAPT regimen than previously recommended (e.g.,</p><p class="s30" style="padding-left: 9pt;text-indent: 0pt;line-height: 9pt;text-align: justify;"><a href="#bookmark30" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">6 months) (</a>Central Illustration<a href="#bookmark39" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">) </a><span class="s9">(6,7)</span><span class="p">. This default</span></p><p style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 140%;text-align: justify;">duration is <span class="s28">ﬂ</span>exible and may be adapted (e.g., pro- longed or shortened) according to patient-speci<span class="s28">ﬁ</span><a href="#bookmark64" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">c risks of ischemia and bleeding </a><span style=" color: #007FAC;">(51)</span>. Patients who are at high bleeding risk, in particular, represent an emerging class of individuals who are more prone to hemorrhagic consequences with long-term DAPT (e.g., due to age, concomitant use of oral anticoag- ulants, thrombocytopenia, active cancer, and so on). In these patients, 1 to 3 months of DAPT may ensure suf<span class="s28">ﬁ</span><a href="#bookmark39" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">cient protection from stent thrombosis reducing the risk of bleeding. As noted in the previous text, this practice is optional in the 2016 ACC/AHA update (COR IIb for 3-month DAPT) and more encouraged in the 2017 ESC update (COR IIa for 3-month DAPT and COR IIb for 1 month DAPT) </a><span style=" color: #007FAC;">(6,7)</span>.</p><p class="s32" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;text-align: justify;">PATIENTS UNDERGOING PCI FOR ACS. <span class="p">The recom-</span></p><p class="s9" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a href="#bookmark65" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">mendation for keeping ACS patients on a 12-month term of DAPT is historically based on the CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) trial </a>(52) <a href="#bookmark66" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">and its PCI-CURE substudy </a>(53)<span style=" color: #000;">.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:38.791pt" cellspacing="0"><tr style="height:28pt"><td style="width:495pt;border-top-style:solid;border-top-width:2pt;border-top-color:#E12A2C;border-left-style:solid;border-left-width:2pt;border-left-color:#E12A2C;border-right-style:solid;border-right-width:2pt;border-right-color:#E12A2C" bgcolor="#DEE9F7"><p class="s56" style="padding-top: 3pt;padding-left: 12pt;padding-right: 92pt;text-indent: 0pt;text-align: left;"><a name="bookmark30">CENTRAL ILLUSTRATION </a><span class="s57">Recommendations for Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention</span></p></td></tr><tr style="height:392pt"><td style="width:495pt;border-left-style:solid;border-left-width:2pt;border-left-color:#E12A2C;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:2pt;border-right-color:#E12A2C"><p class="s58" style="padding-top: 8pt;padding-left: 283pt;padding-right: 24pt;text-indent: 0pt;line-height: 110%;text-align: center;">Recommended duration of DAPT (months) with associated class and level of evidence</p><p class="s58" style="padding-left: 326pt;padding-right: 65pt;text-indent: 0pt;text-align: center;">0 1 3 6 12 30 30+</p><p class="s59" style="padding-top: 10pt;padding-left: 272pt;text-indent: 0pt;text-align: left;">I A IIb A</p><p class="s60" style="padding-top: 8pt;padding-left: 150pt;padding-right: 92pt;text-indent: 3pt;line-height: 108%;text-align: left;">No high                        <span class="s59">I BR                         IIb A </span><span class="s58">bleeding</span></p><p class="s58" style="padding-left: 161pt;text-indent: 0pt;line-height: 11pt;text-align: left;">risk</p><p class="s58" style="padding-left: 91pt;text-indent: 0pt;line-height: 12pt;text-align: left;">Stable <span class="s61">(HBR)</span></p><p class="s58" style="padding-left: 85pt;text-indent: 0pt;line-height: 11pt;text-align: left;">coronary <span class="s62">I A IIb A</span></p><p class="s58" style="padding-top: 2pt;padding-right: 201pt;text-indent: 0pt;line-height: 70%;text-align: right;">artery <span class="s63">IIa C</span></p><p class="s58" style="padding-left: 10pt;padding-right: 293pt;text-indent: 0pt;line-height: 9pt;text-align: center;">disease</p><p class="s58" style="padding-top: 1pt;padding-left: 89pt;text-indent: 0pt;text-align: left;">(SCAD)</p><p class="s64" style="padding-left: 272pt;text-indent: 0pt;line-height: 11pt;text-align: left;">I A <span class="s53">Key:</span></p><p class="s65" style="padding-left: 393pt;text-indent: 0pt;line-height: 8pt;text-align: left;">BMS <span class="s53">Bare metal stent</span></p><p class="s66" style="padding-top: 1pt;padding-left: 159pt;text-indent: 0pt;line-height: 61%;text-align: left;">HBR <span class="s59">IIb C-LD </span><span class="s67">DES </span><span class="s53">Drug-eluting stent</span></p><p class="s65" style="padding-left: 393pt;text-indent: 0pt;line-height: 5pt;text-align: left;">DCB <span class="s53">Drug-coated balloon</span></p><p class="s59" style="padding-left: 272pt;text-indent: 0pt;line-height: 11pt;text-align: left;">IIa B <span class="s65">BRS</span></p><p class="s58" style="padding-top: 5pt;padding-right: 201pt;text-indent: 0pt;line-height: 75%;text-align: right;">Percutaneous <span class="s68">IIb C</span></p><p class="s58" style="padding-left: 10pt;padding-right: 429pt;text-indent: 0pt;line-height: 9pt;text-align: center;">coronary</p><p class="s58" style="padding-top: 1pt;padding-left: 10pt;padding-right: 429pt;text-indent: 0pt;line-height: 110%;text-align: center;">intervention (PCI)</p><p class="s59" style="padding-top: 5pt;padding-left: 296pt;padding-right: 77pt;text-indent: 0pt;text-align: center;">I BR       IIb A</p><p class="s69" style="padding-top: 1pt;padding-left: 86pt;padding-right: 55pt;text-indent: 6pt;line-height: 82%;text-align: left;">Acute             <span class="s70">No HBR                                 </span><span class="s59">I A                                     IIb B </span><span class="s58">coronary</span></p><p class="s58" style="padding-top: 1pt;padding-left: 10pt;padding-right: 293pt;text-indent: 0pt;line-height: 11pt;text-align: center;">syndromes</p><p class="s71" style="padding-left: 93pt;text-indent: 0pt;line-height: 11pt;text-align: left;">(ACS) <span class="s59">IIb C-LD</span></p><p class="s70" style="padding-left: 159pt;text-indent: 0pt;line-height: 18pt;text-align: left;">HBR <span class="s59">IIa B</span></p><p class="s72" style="padding-top: 14pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Capodanno, D. et al. J Am Coll Cardiol. 2018;72(23):2915<span class="s73">–</span>31.</p></td></tr><tr style="height:46pt"><td style="width:495pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:2pt;border-left-color:#E12A2C;border-bottom-style:solid;border-bottom-width:2pt;border-bottom-color:#E12A2C;border-right-style:solid;border-right-width:2pt;border-right-color:#E12A2C"><p class="s36" style="padding-top: 7pt;padding-left: 12pt;padding-right: 14pt;text-indent: 0pt;line-height: 136%;text-align: left;">ACS <span class="s39">¼ </span>acute coronary syndromes; BMS <span class="s39">¼ </span>bare metal stent; B-R <span class="s39">¼ </span>Level of Evidence B based on randomized evidence; BRS <span class="s39">¼ </span>bioresorbable scaffold; CAD <span class="s39">¼ </span>coronary artery disease; C-LD <span class="s39">¼ </span>Level of Evidence C based on limited data; DAPT <span class="s39">¼ </span>dual antiplatelet therapy; DCB <span class="s39">¼ </span>drug-coated balloon; DES <span class="s39">¼ </span>drug-eluting stent;</p><p class="s36" style="padding-left: 12pt;text-indent: 0pt;line-height: 7pt;text-align: left;">HBR <span class="s39">¼ </span>high bleeding risk; PCI <span class="s39">¼ </span>percutaneous coronary intervention; SCAD <span class="s39">¼ </span>stable coronary artery disease.</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="645" height="428" alt="image" src="j.jacc.2018.09.057/Image_014.png"/></span></p><p style="padding-left: 109pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a href="#bookmark39" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">At the time of publication of the ACC/AHA and ESC updates, no available trials of DAPT duration included only patients with ACS, and recommenda- tions were based on subgroup analyses from trials of DAPT duration including a proportion of ACS patients </a><span style=" color: #007FAC;">(6,7)</span>. In patients with ACS undergoing PCI, the recommendation of the 2016 ACC/AHA update for P2Y12 inhibitor therapy, in combination with aspirin (COR I, LOE B), is <span class="s11">“</span>at least 12 months<span class="s11">” </span>regardless of the type of stent implanted (COR I, LOE B). Ticagrelor or prasugrel, if no contraindications exist, should be used in preference to clopidogrel for maintenance</p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse" cellspacing="0"><tr style="height:49pt"><td style="width:36pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="3"><p class="s58" style="padding-top: 8pt;padding-left: 10pt;padding-right: 5pt;text-indent: -1pt;line-height: 178%;text-align: left;">BMS DES</p></td></tr><tr style="height:32pt"><td style="width:6pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:25pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#D7D9DA"><p class="s58" style="padding-left: 3pt;padding-right: 2pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">BMS DES DCB</p></td><td style="width:5pt;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#D7D9DA"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:1pt"><td style="width:6pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:25pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#D7D9DA"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:5pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#D7D9DA"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:5pt"><td style="width:36pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="3"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:8pt"><td style="width:6pt;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:25pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#D7D9DA"><p class="s58" style="padding-top: 1pt;padding-left: 1pt;text-indent: 0pt;line-height: 5pt;text-align: center;">BRS</p></td><td style="width:5pt;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#D7D9DA"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:7pt"><td style="width:6pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:25pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#D7D9DA"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:5pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#D7D9DA"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:14pt"><td style="width:36pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="3"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:8pt"><td style="width:6pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:25pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#D7D9DA"><p class="s58" style="padding-top: 1pt;padding-left: 1pt;text-indent: 0pt;line-height: 4pt;text-align: center;">BMS</p></td><td style="width:5pt;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#D7D9DA"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:7pt"><td style="width:6pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:25pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#D7D9DA"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:5pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#D7D9DA"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:4pt"><td style="width:36pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="3" bgcolor="#D7D9DA"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:8pt"><td style="width:6pt;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:25pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#D7D9DA"><p class="s58" style="padding-top: 1pt;padding-left: 1pt;text-indent: 0pt;line-height: 5pt;text-align: center;">DES</p></td><td style="width:5pt;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#D7D9DA"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:7pt"><td style="width:6pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:25pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#D7D9DA"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:5pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" bgcolor="#D7D9DA"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:10pt"><td style="width:36pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="3"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:20pt"><td style="width:36pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-left-style:solid;border-left-width:1pt;border-left-color:#4C4D4F;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="3"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:132pt"><td style="width:36pt;border-top-style:solid;border-top-width:1pt;border-top-color:#4C4D4F;border-right-style:solid;border-right-width:1pt;border-right-color:#4C4D4F" colspan="3"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"/><p style="padding-left: 9pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a href="#bookmark39" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">therapy (COR IIa, LOE B). DAPT prolongation beyond 12 months may be considered in patients who have tolerated DAPT without a bleeding complication and who are not at high bleeding risk (COR IIb, LOE A) </a><span style=" color: #007FAC;">(6)</span>. Conversely, patients who are at high risk of bleeding or develop signi<span class="s28">ﬁ</span>cant overt bleeding may discontinue DAPT at 6 months (COR IIb, LOE C). Similarly, in the 2017 ESC update, the default duration of DAPT for ACS patients undergoing PCI is also 12 months (COR I, LOE A) and DAPT prolongation for longer than 12 months may be considered in patients who have tolerated DAPT without a bleeding complication</p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse" cellspacing="0"><tr style="height:18pt"><td style="width:278pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="6" bgcolor="#DEE9F7"><p class="s33" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">TABLE 3 <span class="s34">Studies of Dual Antiplatelet Therapy Duration</span></p></td></tr><tr style="height:13pt"><td style="width:38pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt"><p style="padding-top: 3pt;padding-left: 6pt;text-indent: 0pt;text-align: left;"><a href="#bookmark32" style=" color: black; font-family:Tahoma, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 5.5pt;">ACC/AHA</a><a href="#bookmark32" class="s74">*</a></p></td><td style="width:21pt;border-bottom-style:solid;border-bottom-width:1pt"><p style="padding-top: 3pt;padding-left: 4pt;text-indent: 0pt;text-align: left;"><a href="#bookmark32" style=" color: black; font-family:Tahoma, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 5.5pt;">ESC</a><a href="#bookmark32" class="s74">*</a></p></td><td style="width:79pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s35" style="padding-top: 3pt;padding-left: 32pt;padding-right: 32pt;text-indent: 0pt;text-align: center;">Trial</p></td><td style="width:38pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s35" style="padding-top: 3pt;padding-right: 1pt;text-indent: 0pt;text-align: right;">Comparison</p></td><td style="width:29pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s35" style="padding-top: 3pt;text-indent: 0pt;text-align: left;">(Months)</p></td><td style="width:73pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s35" style="padding-top: 3pt;padding-left: 3pt;padding-right: 4pt;text-indent: 0pt;text-align: center;">Design</p></td></tr><tr style="height:11pt"><td style="width:278pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="6" bgcolor="#DEE9F7"><p class="s36" style="padding-top: 1pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">PCI</p></td></tr><tr style="height:13pt"><td style="width:38pt;border-left-style:solid;border-left-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 12pt;text-indent: 0pt;text-align: left;">Yes</p></td><td style="width:21pt"><p class="s36" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Yes</p></td><td style="width:79pt"><p class="s36" style="padding-top: 1pt;padding-left: 14pt;text-indent: 0pt;text-align: left;">RESET (N <span class="s39">¼ </span>2,217)</p></td><td style="width:38pt"><p class="s36" style="padding-top: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: right;">3 vs.</p></td><td style="width:29pt"><p class="s36" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">12</p></td><td style="width:73pt;border-right-style:solid;border-right-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 3pt;padding-right: 4pt;text-indent: 0pt;text-align: center;">Noninferiority</p></td></tr><tr style="height:11pt"><td style="width:38pt;border-left-style:solid;border-left-width:1pt"><p class="s36" style="padding-left: 12pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Yes</p></td><td style="width:21pt"><p class="s36" style="padding-left: 5pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Yes</p></td><td style="width:79pt"><p class="s36" style="padding-left: 8pt;text-indent: 0pt;line-height: 7pt;text-align: left;">OPTIMIZE (N <span class="s39">¼ </span>2,199)</p></td><td style="width:38pt"><p class="s36" style="padding-right: 1pt;text-indent: 0pt;line-height: 7pt;text-align: right;">3 vs.</p></td><td style="width:29pt"><p class="s36" style="text-indent: 0pt;line-height: 7pt;text-align: left;">12</p></td><td style="width:73pt;border-right-style:solid;border-right-width:1pt"><p class="s36" style="padding-left: 3pt;padding-right: 4pt;text-indent: 0pt;line-height: 7pt;text-align: center;">Noninferiority</p></td></tr><tr style="height:11pt"><td style="width:38pt;border-left-style:solid;border-left-width:1pt"><p class="s36" style="padding-left: 12pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Yes</p></td><td style="width:21pt"><p class="s36" style="padding-left: 5pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Yes</p></td><td style="width:79pt"><p class="s36" style="padding-left: 6pt;text-indent: 0pt;line-height: 7pt;text-align: left;">EXCELLENT (N <span class="s39">¼ </span>1,443)</p></td><td style="width:38pt"><p class="s36" style="text-indent: 0pt;line-height: 7pt;text-align: right;">6 vs.</p></td><td style="width:29pt"><p class="s36" style="padding-left: 1pt;text-indent: 0pt;line-height: 7pt;text-align: left;">12</p></td><td style="width:73pt;border-right-style:solid;border-right-width:1pt"><p class="s36" style="padding-left: 3pt;padding-right: 4pt;text-indent: 0pt;line-height: 7pt;text-align: center;">Noninferiority</p></td></tr><tr style="height:11pt"><td style="width:38pt;border-left-style:solid;border-left-width:1pt"><p class="s36" style="padding-left: 12pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Yes</p></td><td style="width:21pt"><p class="s36" style="padding-left: 5pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Yes</p></td><td style="width:79pt"><p class="s36" style="padding-left: 8pt;text-indent: 0pt;line-height: 7pt;text-align: left;">SECURITY (N <span class="s39">¼ </span>1,399)</p></td><td style="width:38pt"><p class="s36" style="text-indent: 0pt;line-height: 7pt;text-align: right;">6 vs.</p></td><td style="width:29pt"><p class="s36" style="padding-left: 1pt;text-indent: 0pt;line-height: 7pt;text-align: left;">12</p></td><td style="width:73pt;border-right-style:solid;border-right-width:1pt"><p class="s36" style="padding-left: 3pt;padding-right: 4pt;text-indent: 0pt;line-height: 7pt;text-align: center;">Noninferiority (halted)</p></td></tr><tr style="height:11pt"><td style="width:38pt;border-left-style:solid;border-left-width:1pt"><p class="s36" style="padding-left: 12pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Yes</p></td><td style="width:21pt"><p class="s36" style="padding-left: 5pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Yes</p></td><td style="width:79pt"><p class="s36" style="padding-left: 6pt;text-indent: 0pt;line-height: 7pt;text-align: left;">ISAR-SAFE (N <span class="s39">¼ </span>4,000)</p></td><td style="width:38pt"><p class="s36" style="text-indent: 0pt;line-height: 7pt;text-align: right;">6 vs.</p></td><td style="width:29pt"><p class="s36" style="padding-left: 1pt;text-indent: 0pt;line-height: 7pt;text-align: left;">12</p></td><td style="width:73pt;border-right-style:solid;border-right-width:1pt"><p class="s36" style="padding-left: 3pt;padding-right: 4pt;text-indent: 0pt;line-height: 7pt;text-align: center;">Noninferiority (halted)</p></td></tr><tr style="height:11pt"><td style="width:38pt;border-left-style:solid;border-left-width:1pt"><p class="s36" style="padding-left: 12pt;text-indent: 0pt;line-height: 7pt;text-align: left;">No</p></td><td style="width:21pt"><p class="s36" style="padding-left: 6pt;text-indent: 0pt;line-height: 7pt;text-align: left;">No</p></td><td style="width:79pt"><p class="s36" style="padding-left: 5pt;text-indent: 0pt;line-height: 7pt;text-align: left;">I-LOVE-IT-2 (N <span class="s39">¼ </span>1,829)</p></td><td style="width:38pt"><p class="s36" style="text-indent: 0pt;line-height: 7pt;text-align: right;">6 vs.</p></td><td style="width:29pt"><p class="s36" style="padding-left: 1pt;text-indent: 0pt;line-height: 7pt;text-align: left;">12</p></td><td style="width:73pt;border-right-style:solid;border-right-width:1pt"><p class="s36" style="padding-left: 3pt;padding-right: 4pt;text-indent: 0pt;line-height: 7pt;text-align: center;">Noninferiority</p></td></tr><tr style="height:11pt"><td style="width:38pt;border-left-style:solid;border-left-width:1pt"><p class="s36" style="padding-left: 12pt;text-indent: 0pt;line-height: 7pt;text-align: left;">No</p></td><td style="width:21pt"><p class="s36" style="padding-left: 6pt;text-indent: 0pt;line-height: 7pt;text-align: left;">No</p></td><td style="width:79pt"><p class="s36" style="padding-left: 8pt;text-indent: 0pt;line-height: 7pt;text-align: left;">IVUS-XPL (N <span class="s39">¼ </span>1,400)</p></td><td style="width:38pt"><p class="s36" style="text-indent: 0pt;line-height: 7pt;text-align: right;">6 vs.</p></td><td style="width:29pt"><p class="s36" style="padding-left: 1pt;text-indent: 0pt;line-height: 7pt;text-align: left;">12</p></td><td style="width:73pt;border-right-style:solid;border-right-width:1pt"><p class="s36" style="padding-left: 3pt;padding-right: 4pt;text-indent: 0pt;line-height: 7pt;text-align: center;">Noninferiority</p></td></tr><tr style="height:11pt"><td style="width:38pt;border-left-style:solid;border-left-width:1pt"><p class="s36" style="padding-left: 12pt;text-indent: 0pt;line-height: 7pt;text-align: left;">No</p></td><td style="width:21pt"><p class="s36" style="padding-left: 6pt;text-indent: 0pt;line-height: 7pt;text-align: left;">No</p></td><td style="width:79pt"><p class="s36" style="padding-left: 7pt;text-indent: 0pt;line-height: 7pt;text-align: left;">OPTIMA-C (N <span class="s39">¼ </span>1,368)</p></td><td style="width:38pt"><p class="s36" style="text-indent: 0pt;line-height: 7pt;text-align: right;">6 vs.</p></td><td style="width:29pt"><p class="s36" style="padding-left: 1pt;text-indent: 0pt;line-height: 7pt;text-align: left;">12</p></td><td style="width:73pt;border-right-style:solid;border-right-width:1pt"><p class="s36" style="padding-left: 3pt;padding-right: 4pt;text-indent: 0pt;line-height: 7pt;text-align: center;">Noninferiority</p></td></tr><tr style="height:11pt"><td style="width:38pt;border-left-style:solid;border-left-width:1pt"><p class="s36" style="padding-left: 12pt;text-indent: 0pt;line-height: 7pt;text-align: left;">No</p></td><td style="width:21pt"><p class="s36" style="padding-left: 6pt;text-indent: 0pt;line-height: 7pt;text-align: left;">No</p></td><td style="width:79pt"><p class="s36" style="padding-left: 11pt;text-indent: 0pt;line-height: 7pt;text-align: left;">NIPPON (N <span class="s39">¼ </span>2,772)</p></td><td style="width:38pt"><p class="s36" style="padding-right: 1pt;text-indent: 0pt;line-height: 7pt;text-align: right;">6 vs.</p></td><td style="width:29pt"><p class="s36" style="text-indent: 0pt;line-height: 7pt;text-align: left;">24</p></td><td style="width:73pt;border-right-style:solid;border-right-width:1pt"><p class="s36" style="padding-left: 3pt;padding-right: 4pt;text-indent: 0pt;line-height: 7pt;text-align: center;">Noninferiority (halted)</p></td></tr><tr style="height:11pt"><td style="width:38pt;border-left-style:solid;border-left-width:1pt"><p class="s36" style="padding-left: 12pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Yes</p></td><td style="width:21pt"><p class="s36" style="padding-left: 5pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Yes</p></td><td style="width:79pt"><p class="s36" style="padding-left: 9pt;text-indent: 0pt;line-height: 7pt;text-align: left;">PRODIGY (N <span class="s39">¼ </span>1,970)</p></td><td style="width:38pt"><p class="s36" style="padding-right: 1pt;text-indent: 0pt;line-height: 7pt;text-align: right;">6 vs.</p></td><td style="width:29pt"><p class="s36" style="text-indent: 0pt;line-height: 7pt;text-align: left;">24</p></td><td style="width:73pt;border-right-style:solid;border-right-width:1pt"><p class="s36" style="padding-left: 3pt;padding-right: 4pt;text-indent: 0pt;line-height: 7pt;text-align: center;">Superiority</p></td></tr><tr style="height:11pt"><td style="width:38pt;border-left-style:solid;border-left-width:1pt"><p class="s36" style="padding-left: 12pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Yes</p></td><td style="width:21pt"><p class="s36" style="padding-left: 5pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Yes</p></td><td style="width:79pt"><p class="s36" style="padding-left: 13pt;text-indent: 0pt;line-height: 7pt;text-align: left;">ITALIC (N <span class="s39">¼ </span>1,822)</p></td><td style="width:38pt"><p class="s36" style="padding-right: 1pt;text-indent: 0pt;line-height: 7pt;text-align: right;">6 vs.</p></td><td style="width:29pt"><p class="s36" style="text-indent: 0pt;line-height: 7pt;text-align: left;">24</p></td><td style="width:73pt;border-right-style:solid;border-right-width:1pt"><p class="s36" style="padding-left: 3pt;padding-right: 4pt;text-indent: 0pt;line-height: 7pt;text-align: center;">Noninferiority (halted)</p></td></tr><tr style="height:11pt"><td style="width:38pt;border-left-style:solid;border-left-width:1pt"><p class="s36" style="padding-left: 12pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Yes</p></td><td style="width:21pt"><p class="s36" style="padding-left: 5pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Yes</p></td><td style="width:79pt"><p class="s36" style="padding-left: 12pt;text-indent: 0pt;line-height: 7pt;text-align: left;">ARCTIC (N <span class="s39">¼ </span>1,259)</p></td><td style="width:38pt"><p class="s36" style="text-indent: 0pt;line-height: 7pt;text-align: right;">12 vs.</p></td><td style="width:29pt"><p class="s36" style="padding-left: 1pt;text-indent: 0pt;line-height: 7pt;text-align: left;">18</p></td><td style="width:73pt;border-right-style:solid;border-right-width:1pt"><p class="s36" style="padding-left: 3pt;padding-right: 4pt;text-indent: 0pt;line-height: 7pt;text-align: center;">Superiority</p></td></tr><tr style="height:11pt"><td style="width:38pt;border-left-style:solid;border-left-width:1pt"><p class="s36" style="padding-left: 12pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Yes</p></td><td style="width:21pt"><p class="s36" style="padding-left: 5pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Yes</p></td><td style="width:79pt"><p class="s36" style="padding-left: 14pt;text-indent: 0pt;line-height: 7pt;text-align: left;">DAPT (N <span class="s39">¼ </span>9,961)</p></td><td style="width:38pt"><p class="s36" style="text-indent: 0pt;line-height: 7pt;text-align: right;">12 vs.</p></td><td style="width:29pt"><p class="s36" style="padding-left: 1pt;text-indent: 0pt;line-height: 7pt;text-align: left;">30</p></td><td style="width:73pt;border-right-style:solid;border-right-width:1pt"><p class="s36" style="padding-left: 3pt;padding-right: 4pt;text-indent: 0pt;line-height: 7pt;text-align: center;">Superiority</p></td></tr><tr style="height:11pt"><td style="width:38pt;border-left-style:solid;border-left-width:1pt"><p class="s36" style="padding-left: 12pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Yes</p></td><td style="width:21pt"><p class="s36" style="padding-left: 5pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Yes</p></td><td style="width:79pt"><p class="s36" style="padding-left: 7pt;text-indent: 0pt;line-height: 7pt;text-align: left;">DES-LATE (N <span class="s39">¼ </span>5,045)</p></td><td style="width:38pt"><p class="s36" style="text-indent: 0pt;line-height: 7pt;text-align: right;">12 vs.</p></td><td style="width:29pt"><p class="s36" style="padding-left: 1pt;text-indent: 0pt;line-height: 7pt;text-align: left;">36</p></td><td style="width:73pt;border-right-style:solid;border-right-width:1pt"><p class="s36" style="padding-left: 3pt;padding-right: 4pt;text-indent: 0pt;line-height: 7pt;text-align: center;">Superiority</p></td></tr><tr style="height:9pt"><td style="width:38pt;border-left-style:solid;border-left-width:1pt"><p class="s36" style="padding-left: 12pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Yes</p></td><td style="width:21pt"><p class="s36" style="padding-left: 6pt;text-indent: 0pt;line-height: 7pt;text-align: left;">No</p></td><td style="width:79pt"><p class="s36" style="padding-left: 8pt;text-indent: 0pt;line-height: 7pt;text-align: left;">OPTIDUAL (N <span class="s39">¼ </span>1,385)</p></td><td style="width:38pt"><p class="s36" style="text-indent: 0pt;line-height: 7pt;text-align: right;">12 vs.</p></td><td style="width:29pt"><p class="s36" style="padding-left: 1pt;text-indent: 0pt;line-height: 7pt;text-align: left;">48</p></td><td style="width:73pt;border-right-style:solid;border-right-width:1pt"><p class="s36" style="padding-left: 3pt;padding-right: 4pt;text-indent: 0pt;line-height: 7pt;text-align: center;">Superiority (halted)</p></td></tr><tr style="height:11pt"><td style="width:278pt;border-left-style:solid;border-left-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="6" bgcolor="#DEE9F7"><p class="s36" style="padding-top: 1pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">ACS-PCI</p></td></tr><tr style="height:36pt"><td style="width:38pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 12pt;padding-right: 17pt;text-indent: 0pt;line-height: 144%;text-align: justify;">No No No</p></td><td style="width:21pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 6pt;padding-right: 6pt;text-indent: 0pt;line-height: 144%;text-align: justify;">No No No</p></td><td style="width:79pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 4pt;padding-right: 3pt;text-indent: 0pt;line-height: 144%;text-align: center;">DAPT-STEMI (N <span class="s39">¼ </span>870) REDUCE (N <span class="s39">¼ </span>1,496) SMART-DATE (N <span class="s39">¼ </span>2,172)</p></td><td style="width:38pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 22pt;text-indent: 0pt;text-align: left;">6 vs.</p><p class="s36" style="padding-top: 3pt;padding-left: 23pt;text-indent: 0pt;text-align: left;">3 vs.</p><p class="s36" style="padding-top: 3pt;padding-left: 22pt;text-indent: 0pt;text-align: left;">6 vs.</p></td><td style="width:29pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 1pt;text-indent: 0pt;text-align: left;">12</p><p class="s36" style="padding-top: 3pt;text-indent: 0pt;text-align: left;">12</p><p class="s36" style="padding-top: 3pt;padding-left: 1pt;text-indent: 0pt;text-align: left;">12</p></td><td style="width:73pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 16pt;padding-right: 17pt;text-indent: 0pt;line-height: 144%;text-align: justify;">Noninferiority Noninferiority Noninferiority</p></td></tr><tr style="height:30pt"><td style="width:278pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="6"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s41" style="padding-left: 11pt;padding-right: 9pt;text-indent: -5pt;line-height: 146%;text-align: left;"><a href="#bookmark27" style=" color: black; font-family:&quot;Century Gothic&quot;, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 5pt;">*The availability status at the time of the ACC/AHA and ESC guidelines publication is indicated. Abbreviations as in </a><span style=" color: #007FAC; font-family:Tahoma, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 5pt;">Table 1</span>.</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"/><p style="padding-top: 5pt;padding-left: 41pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a href="#bookmark40" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;" name="bookmark10">(COR IIb, LOE A), whereas discontinuation at 6 months should be considered in patients who are at high bleeding risk (COR IIa, LOE B) </a><span style=" color: #007FAC;">(7)</span>. As noted in the following text, the 2017 ESC update is more speci<span class="s28">ﬁ</span>c on the drug to be preferentially used in combination with aspirin beyond 1 year of therapy in patients with prior MI. Based on the results of the<a name="bookmark11">&zwnj;</a><a name="bookmark12">&zwnj;</a></p><p style="padding-left: 41pt;text-indent: 0pt;line-height: 1pt;text-align: left;">PEGASUS</p><p class="s11" style="padding-left: 78pt;text-indent: 0pt;line-height: 8pt;text-align: justify;">–<span class="p">TIMI 54 (Prevention of Cardiovascular</span></p><p style="padding-top: 3pt;padding-left: 41pt;text-indent: 0pt;line-height: 140%;text-align: justify;">Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin<span class="s11">–</span>Thrombolysis In Myocardial Infarction 54) trial, ticagrelor may be preferred over clopidogrel or prasugrel (COR IIb, LOE B).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s9" style="padding-left: 41pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><span class="s32">PATIENTS UNDERGOING CABG. </span><a href="#bookmark39" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">No dedicated ran- domized study exists to guide the duration of DAPT after CABG. Based on the 2016 ACC/AHA update, DAPT must be reinstituted as soon as possible after CABG in patients with ACS or recent stent implanta- tion (COR I, LOE C) and maintained to complete the recommended 12-month period </a>(6)<a href="#bookmark58" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">. Twelve-month DAPT may also be considered in patients with stable CAD to improve vein graft patency (COR IIb, LOE B). Similar to previous PCI guidelines </a>(32)<span style=" color: #000;">, no recom- mendation is given with respect to the timing of discontinuation. However, the topic was previously covered in great details in guidelines for NSTE-ACS</span></p><p class="s9" style="padding-left: 41pt;text-indent: 0pt;line-height: 140%;text-align: justify;">(14) <a href="#bookmark67" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">and for CABG </a>(54)<span style=" color: #000;">, where patients referred for elective CABG are recommended discontinuation of clopidogrel and ticagrelor for at least 5 days before surgery (COR I, LOE B) and prasugrel discontinuation for at least 7 days before surgery (COR I, LOE C). In case of urgent CABG, it may be reasonable to perform</span></p><p style="padding-left: 41pt;text-indent: 0pt;line-height: 10pt;text-align: justify;">surgery <span class="s43">&lt;</span>5 days after clopidogrel or ticagrelor has</p><p style="padding-left: 41pt;text-indent: 0pt;line-height: 114%;text-align: justify;">been discontinued and <span class="s43">&lt;</span>7 days after prasugrel has been discontinued (COR IIb, LOE C), but no sooner</p><p style="padding-top: 2pt;padding-left: 41pt;text-indent: 0pt;line-height: 140%;text-align: justify;">than 24 h (COR I, LOE B). On the other hand, the 2017 ESC update de<span class="s28">ﬁ</span>nes a role for the heart team in determining the individual bleeding and ischemic risks, and guiding the timing of CABG as well as the appropriate antithrombotic management (COR I, LOE</p></li><li><p style="padding-left: 41pt;text-indent: 0pt;line-height: 140%;text-align: left;"><span style=" color: #007FAC;">(7)</span>. Before CABG, the P2Y12 inhibitor should be discontinued to decrease the risk of perioperative bleeding (at least 3 days for ticagrelor, 5 days for clopidogrel, and 7 days for prasugrel; COR IIa, LOE B). Aspirin is recommended throughout the periopera- tive period (COR I, LOE C), while the P2Y12 inhibitor must be resumed as soon as possible in patients with ACS and those who recently received a stent (COR I, LOE C). In patients with prior MI at high risk of bleeding, 6-month DAPT should be considered as a suf<span class="s28">ﬁ</span>cient timeframe (COR IIa, LOE C), but those with</p></li></ol></ol><p style="padding-left: 41pt;text-indent: 0pt;line-height: 124%;text-align: left;">prior MI and low risk of bleeding may be considered for a <span class="s43">&gt;</span>12- and up to 36-month term of DAPT (COR IIb,</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 6pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a name="bookmark31">LOE C). Finally, a COR IIb, LOE B is given for platelet function testing to guide decisions on timing of CABG in patients who have recently received P2Y12 inhibitors.</a><a name="bookmark32">&zwnj;</a></p><p style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: justify;"><span class="s32">PATIENTS WITH PRIOR MI. </span>In the PEGASUS<span class="s11">–</span>TIMI 54</p><p class="s9" style="padding-top: 3pt;padding-left: 6pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a href="#bookmark68" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">trial, 2 doses of ticagrelor (60 and 90 mg twice daily) were studied, and both decreased the incidence of ischemic events in 21,162 patients with a history of prior MI from 1 to 3 years earlier, but also both increased the incidence of major bleeding </a>(55)<a href="#bookmark39" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">. The 60-mg twice daily dose was subsequently approved by regulatory authorities in both the United States and Europe. In the 2016 ACC/AHA update, continued DAPT is given a COR IIb, LOE B for patients with an MI that occurred 1 to 3 years earlier and who have tolerated DAPT without bleeding or who are not at high bleeding risk </a>(6)<a href="#bookmark40" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">. In  the 2017 ESC update, the same COR IIb, LOE B is given for DAPT continuation with ticagrelor in patients with MI and high ischemic risk who have tolerated DAPT without a bleeding complication, in preference to prasugrel or clopi- dogrel </a>(7)<span style=" color: #000;">.</span></p><p class="s32" style="padding-top: 3pt;padding-left: 6pt;text-indent: 0pt;text-align: justify;">PATIENTS WITH ACS MEDICALLY MANAGED. <span class="p">Pa-</span></p><p class="s9" style="padding-top: 3pt;padding-left: 6pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a href="#bookmark69" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">tients with ACS who were medically managed were included in the CURE trial for clopidogrel </a>(56)<a href="#bookmark70" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">, the TRILOGY ACS (Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes) trial for prasugrel </a>(57)<span style=" color: #000;">, and the</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 109pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a href="#bookmark45" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;" name="bookmark13">PLATO trial for ticagrelor </a><span style=" color: #007FAC;">(12)</span>. Among these studies, TRILOGY ACS included only ACS patients with no invasive management, and they were not found to derive a signi<span class="s28">ﬁ</span>cant ischemic bene<span class="s28">ﬁ</span><a href="#bookmark70" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">t from prasugrel compared with clopidogrel </a><span style=" color: #007FAC;">(57)</span>. In the studies of clopidogrel  and ticagrelor, the  treatment  effects  of the drugs were consistent regardless of whether the ACS was managed invasively or not. Based on this data, in the 2016 ACC/AHA update, 12-month DAPT with aspirin and clopidogrel or ticagrelor is given a COR I, LOE B for patients with ACS who are managed<a name="bookmark14">&zwnj;</a></p><p style="padding-top: 5pt;padding-left: 9pt;text-indent: 0pt;line-height: 140%;text-align: justify;">Perioperative discontinuation of P2Y12 inhibitors should be considered at least 3 days before surgery for ticagrelor, at least 5 days for clopidogrel, and at least 7 days for prasugrel (COR IIa, LOE B). If both oral antiplatelet agents have to be discontinued due to high risk of bleeding, a bridging strategy with intra- venous antiplatelet agents may be considered, espe- cially if surgery has to be performed within 1 month after stent implantation (COR IIb, LOE C).</p><p class="s31" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;line-height: 12pt;text-align: left;">ANTIPLATELET THERAPY IN PATIENTS ON ORAL ANTICOAGULATION</p><p style="padding-left: 109pt;text-indent: 0pt;line-height: 6pt;text-align: left;">with medical therapy alone, with preference to tica-       <span class="s75">                                                                                                              </span></p><p style="padding-top: 3pt;padding-left: 109pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a href="#bookmark39" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">grelor (COR IIa, LOE B) and an option for extending DAPT beyond 12 months in patients who are at low risk of bleeding (COR IIb, LOE A) </a><span style=" color: #007FAC;">(6)</span><a href="#bookmark40" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">. The 2017 ESC update provide similar recommendations but also additional statements, with slightly different COR and/or LOE for key recommendations </a><span style=" color: #007FAC;">(7)</span>. In partic- ular, 12-month DAPT with aspirin and clopidogrel or ticagrelor is given a COR I, LOE A, with ticagrelor recommended over clopidogrel if the bleeding risk is acceptable (COR I, LOE B). The duration of DAPT should be shortened to 1 month for patients at high bleeding risk (COR IIa, LOE C). Patients with prior MI with <span class="s11">“</span>PEGASUS<span class="s11">–</span>TIMI 54-like<span class="s11">” </span>characteristics are candidate to DAPT with ticagrelor (COR IIb, LOE B) or clopidogrel (COR IIb, LOE C) for longer than 12 months if the bleeding risk is acceptable. Prasugrel is not recommended in this context (COR III, LOE B).</p><p class="s32" style="padding-top: 5pt;padding-left: 109pt;text-indent: 0pt;text-align: justify;">DAPT IN PATIENTS UNDERGOING NONCARDIAC</p><p class="s32" style="padding-top: 3pt;padding-left: 109pt;text-indent: 0pt;line-height: 140%;text-align: justify;">SURGERY. <a href="#bookmark39" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">Both the ACC/AHA and ESC updates recommend the use of a multidisciplinary approach to antithrombotic management in the perioperative period (COR IIa, LOE C) </a><span class="s9">(6,7)</span><span class="p">. The 2016 ACC/AHA</span></p><p style="padding-left: 109pt;text-indent: 0pt;line-height: 140%;text-align: justify;">update recommends delaying noncardiac surgery 1 month after implantation of bare-metal stents and</p><p style="padding-left: 109pt;text-indent: 0pt;line-height: 140%;text-align: justify;">6 months  after implantation  of drug-eluting stents (COR I, LOE B), although a shorter period of 3 months may be considered if the risk of further delaying surgery is greater than the expected  risks of stent thrombosis (COR IIb, LOE C). Aspirin should be continued throughout the perioperative period and the P2Y12 inhibitor must be resumed as soon as possible postoperatively (COR I, LOE C), which is also recommended by the 2017 ESC update with the same COR but LOE B. No recommendation is given for bridging P2Y12 inhibitors in patients requiring tem- porary perioperative discontinuation of DAPT before surgery. Based on the 2017 ESC update, after PCI, surgery should occur no sooner than 1  month irre- spective of the stent type (COR IIa, LOE B) and may occur no sooner than 6 months in case of recent MI or other high ischemic-risk features (COR IIb, LOE C).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s9" style="padding-left: 9pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><span style=" color: #000;">The 2016 ACC/AHA update does not provide speci</span><span class="s28">ﬁ</span><a href="#bookmark39" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">c recommendations for patients who require concomi- tant antiplatelet and anticoagulant therapy </a>(6)<a href="#bookmark71" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">, which is a topic covered by a North  American consensus document to which they refer to and which has been recently updated after the release of the guidelines </a>(58,59)<span style=" color: #000;">; however, the update gives general guidance on the approach to such patients. Moreover, none of the trials using the non</span><span class="s11">–</span><a href="#bookmark72" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">vitamin K  oral antagonists were available at the time these recommendations were written. In contrast, the 2017 ESC update covers the topic based essentially on 3 randomized trials that investigated antithrombotic strategies to improve the safety of triple antithrombotic therapy with oral anticoagulation and DAPT </a><a href="#bookmark72" class="s8">(60</a><a href="#bookmark72" class="s14">–</a>62)<span style=" color: #000;">. Importantly, none of these studies were adequately powered for detecting differences in ischemic endpoints. The re- sults of an additional trial of PCI patients with atrial </span><span class="s28">ﬁ</span><a href="#bookmark73" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">brillation, showing that dual therapy with dabiga- tran at the doses of 150 or 110 mg reduces bleeding as compared  with  triple antithrombotic therapy,  were not available at the time of publication of both the ACC/AHA and ESC updates </a>(63)<a href="#bookmark74" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">. Further guidance on the topic in the context of similar recommendations is given by a recent European expert consensus docu- ment </a>(64)<span style=" color: #000;">.</span></p><p style="padding-left: 9pt;text-indent: 9pt;line-height: 140%;text-align: justify;">The 2017 ESC update emphasizes the need for implementing strategies to minimize PCI-related complications, including risk strati<span class="s28">ﬁ</span>cation for ischemia and bleeding, keeping triple antithrombotic therapy to the shortest possible duration with dual antithrombotic therapy as an alternative, using non<span class="s11">– </span>vitamin K antagonist oral anticoagulants whenever possible instead of vitamin K antagonists (at the lowest approved dose effective for stroke prevention tested in atrial <span class="s28">ﬁ</span><a href="#bookmark40" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">brillation trials when combined with antiplatelet drugs [COR IIa, LOE C]), considering an INR in the lowest part of the therapeutic range in case of warfarin use (COR IIa, LOE C), and using proton pump inhibitors routinely </a><span style=" color: #007FAC;">(7)</span>. For patients in whom concerns about the risk of ischemic complications</p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:41.964pt" cellspacing="0"><tr style="height:18pt"><td style="width:496pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="5" bgcolor="#DEE9F7"><p class="s33" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;"><a name="bookmark15">FIGURE 4 </a><span class="s34">Summary of Recommendations for DAPT in Patients Undergoing CABG or Referred to Medical Therapy After Coronary Angiography</span><a name="bookmark33">&zwnj;</a></p></td></tr><tr style="height:198pt"><td style="width:79pt;border-left-style:solid;border-left-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s58" style="padding-left: 13pt;padding-right: 6pt;text-indent: 0pt;line-height: 106%;text-align: center;">Coronary artery bypass grafting (CABG)</p></td><td style="width:63pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s58" style="padding-top: 9pt;padding-left: 11pt;padding-right: 14pt;text-indent: 0pt;line-height: 106%;text-align: center;">Stable coronary artery disease (SCAD)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s58" style="padding-left: 7pt;padding-right: 10pt;text-indent: 0pt;line-height: 106%;text-align: center;">Acute coronary syndromes (ACS)</p></td><td style="width:84pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s58" style="padding-left: 10pt;padding-right: 36pt;text-indent: 2pt;line-height: 106%;text-align: center;">No high bleeding risk (HBR)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s58" style="padding-top: 7pt;padding-left: 9pt;padding-right: 37pt;text-indent: 0pt;text-align: center;">HBR</p></td><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s58" style="text-indent: 0pt;text-align: right;">0</p></td><td style="width:226pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" rowspan="5"><p class="s58" style="padding-top: 8pt;padding-left: 11pt;padding-right: 34pt;text-indent: 0pt;line-height: 106%;text-align: left;">Recommended duration of DAPT (months) with associated class and level of evidence</p><p class="s58" style="padding-top: 1pt;padding-left: 30pt;text-indent: 0pt;text-align: left;">1 3 6 12 30 30+</p><p class="s59" style="padding-top: 9pt;padding-left: 1pt;text-indent: 0pt;text-align: left;">IIb B-NR</p><p class="s76" style="padding-top: 6pt;padding-right: 6pt;text-indent: 0pt;line-height: 119%;text-align: left;">No indication for dual antiplatelet therapy (DAPT) unless concomitant or prior indication overrides</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s59" style="padding-left: 1pt;text-indent: 0pt;text-align: left;">I C-LD</p><p class="s59" style="padding-top: 8pt;text-indent: 0pt;text-align: left;">I C IIb B</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s59" style="padding-right: 180pt;text-indent: 0pt;line-height: 170%;text-align: left;">IIb C-LD IIa C</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s59" style="padding-left: 1pt;text-indent: 0pt;text-align: left;">III B-R</p><p class="s76" style="padding-top: 8pt;text-indent: 0pt;text-align: left;">No indication for DAPT</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s59" style="padding-top: 8pt;text-indent: 0pt;text-align: left;">I B-R IIb A</p><p class="s59" style="padding-top: 7pt;text-indent: 0pt;text-align: left;">I A IIb B</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s59" style="padding-right: 180pt;text-indent: 0pt;line-height: 170%;text-align: left;">IIb C-LD IIa C</p></td></tr><tr style="height:51pt"><td style="width:79pt;border-left-style:solid;border-left-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:63pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s58" style="padding-top: 9pt;padding-left: 11pt;padding-right: 12pt;text-indent: 0pt;text-align: center;">SCAD</p></td><td style="width:84pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:44pt"><td style="width:79pt;border-left-style:solid;border-left-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s58" style="padding-left: 26pt;padding-right: 18pt;text-indent: 0pt;line-height: 106%;text-align: left;">Medical therapy</p></td><td style="width:63pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:84pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s58" style="padding-top: 8pt;padding-left: 9pt;padding-right: 37pt;text-indent: 0pt;text-align: center;">No HBR</p></td><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:21pt"><td style="width:79pt;border-left-style:solid;border-left-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:63pt"><p class="s58" style="padding-top: 5pt;padding-left: 11pt;padding-right: 12pt;text-indent: 0pt;text-align: center;">ACS</p></td><td style="width:84pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:43pt"><td style="width:79pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:63pt;border-bottom-style:solid;border-bottom-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:84pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s58" style="padding-top: 6pt;padding-left: 9pt;padding-right: 37pt;text-indent: 0pt;text-align: center;">HBR</p></td><td style="width:44pt;border-bottom-style:solid;border-bottom-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:46pt"><td style="width:496pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="5"><p class="s36" style="padding-top: 7pt;padding-left: 11pt;padding-right: 15pt;text-indent: 0pt;line-height: 136%;text-align: left;">ACS <span class="s39">¼ </span>acute coronary syndromes; BMS <span class="s39">¼ </span>bare metal stent; B-R <span class="s39">¼ </span>Level of Evidence B based on randomized evidence; CAD <span class="s39">¼ </span>coronary artery disease; CABG <span class="s39">¼ </span>coronary artery bypass grafting; C-LD <span class="s39">¼ </span>Level of Evidence C based on limited data; DAPT <span class="s39">¼ </span>dual antiplatelet therapy; HBR <span class="s39">¼ </span>high bleeding risk; PCI <span class="s39">¼ </span>percutaneous coronary intervention; SCAD <span class="s39">¼ </span>stable coronary artery disease.</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="624" height="192" alt="image" src="j.jacc.2018.09.057/Image_015.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="624" height="210" alt="image" src="j.jacc.2018.09.057/Image_016.png"/></span></p><p style="padding-top: 5pt;padding-left: 41pt;text-indent: 0pt;line-height: 140%;text-align: justify;">prevail, 1 month of triple antithrombotic therapy with OAC, aspirin, and clopidogrel should be recom- mended irrespective of the type of stent used (COR IIa, LOE B), but may be considered up to 6 months in patients who are at high ischemic risk due to ACS or other anatomical/procedural characteristics that outweigh the risk of bleeding (COR IIa, LOE B). When the period of triple antithrombotic therapy is concluded, a dual antithrombotic regimen with OAC and aspirin or clopidogrel should be recommended up to 12 months (COR IIa, LOE A), followed by OAC alone (COR IIa, LOE B). In patients where concerns about the risk of bleeding complications prevail, triple antithrombotic therapy should not be prolonged beyond 1 month (COR IIa, LOE B) and should be even avoided using double antithrombotic therapy with OAC and clopidogrel as an alternative (COR IIa,</p><p style="padding-top: 5pt;padding-left: 9pt;text-indent: 0pt;line-height: 140%;text-align: justify;">LOE A). When rivaroxaban is used in combination with aspirin and/or clopidogrel, the 15-mg once-daily dose of rivaroxaban may be used instead of the conventional 20-mg once-daily dose (COR IIb, LOE B). The use of ticagrelor or prasugrel is not recommended as part of triple antithrombotic therapy (COR III, LOE C).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s31" style="padding-left: 9pt;text-indent: 0pt;text-align: justify;">NEW EVIDENCE AND ONGOING STUDIES</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 9pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="272" height="0" alt="image" src="j.jacc.2018.09.057/Image_017.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 9pt;text-indent: 0pt;line-height: 138%;text-align: justify;">Several randomized clinical trials have been pub- lished after the release of the ACC/AHA and ESC up- dates on DAPT, which have the potential to in<span class="s28">ﬂ</span><a href="#bookmark34" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">uence or inform the COR and/or reinforce the relative LOE, and other trials are ongoing (</a><span class="s30">Figure 5</span>). A description of trials looking at alternative antithrombotic strate- gies, such as the adjunctive use of oral anticoagulant</p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:38.166pt" cellspacing="0"><tr style="height:18pt"><td style="width:496pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="6" bgcolor="#DEE9F7"><p class="s33" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;"><a name="bookmark16">FIGURE 5 </a><span class="s34">New Evidence and Ongoing Studies in the Field of DAPT</span><a name="bookmark17">&zwnj;</a><a name="bookmark34">&zwnj;</a></p></td></tr><tr style="height:50pt"><td style="width:116pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt" rowspan="22"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s77" style="padding-left: 25pt;padding-right: 28pt;text-indent: 0pt;text-align: left;">Focused updates on DAPT</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s53" style="padding-top: 5pt;padding-left: 25pt;padding-right: 15pt;text-indent: 0pt;text-align: left;">Trials of aspirin dosing or aspirin-free strategies</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s53" style="padding-top: 7pt;padding-left: 25pt;padding-right: 28pt;text-indent: 0pt;line-height: 87%;text-align: left;">Trials of P2Y<span class="s54">12 </span>inhibitors choice</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s53" style="padding-top: 7pt;padding-left: 25pt;padding-right: 18pt;text-indent: 0pt;text-align: left;">TriaIs of de-escalation, platelet function testing, genotyping</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s53" style="padding-left: 25pt;padding-right: 28pt;text-indent: 0pt;text-align: left;">TriaIs of DAPT duration</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s53" style="padding-top: 8pt;padding-left: 25pt;padding-right: 17pt;text-indent: 0pt;text-align: left;">TriaIs of PCI and atrial fibrillation</p></td><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 18pt;text-indent: 0pt;text-align: left;"><span><img width="48" height="29" alt="image" src="j.jacc.2018.09.057/Image_018.jpg"/></span></p><p class="s78" style="padding-top: 3pt;padding-left: 18pt;padding-right: 12pt;text-indent: 0pt;text-align: center;">ACC/AHA</p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span><img width="26" height="25" alt="image" src="j.jacc.2018.09.057/Image_019.jpg"/></span></p><p class="s78" style="padding-top: 3pt;padding-left: 12pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">ESC</p></td><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:64pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:120pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:23pt"><td style="width:67pt"><p class="s77" style="padding-top: 6pt;padding-left: 18pt;padding-right: 12pt;text-indent: 0pt;text-align: center;">2016</p></td><td style="width:62pt"><p class="s77" style="padding-top: 6pt;padding-left: 12pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">2017</p></td><td style="width:67pt"><p class="s77" style="padding-top: 6pt;padding-left: 8pt;padding-right: 6pt;text-indent: 0pt;text-align: center;">2018</p></td><td style="width:64pt"><p class="s77" style="padding-top: 6pt;padding-left: 7pt;padding-right: 9pt;text-indent: 0pt;text-align: center;">2019</p></td><td style="width:120pt;border-right-style:solid;border-right-width:1pt"><p class="s77" style="padding-top: 6pt;padding-left: 21pt;text-indent: 0pt;text-align: left;">2020</p></td></tr><tr style="height:15pt"><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:64pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:120pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s79" style="padding-left: 13pt;text-indent: 0pt;line-height: 6pt;text-align: left;">ADAPTABLE</p></td></tr><tr style="height:11pt"><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:67pt"><p class="s79" style="padding-top: 3pt;padding-left: 8pt;padding-right: 6pt;text-indent: 0pt;line-height: 6pt;text-align: center;">GLOBAL LEADERS</p></td><td style="width:64pt"><p class="s79" style="padding-top: 3pt;padding-left: 7pt;padding-right: 9pt;text-indent: 0pt;line-height: 6pt;text-align: center;">TWILIGHT</p></td><td style="width:120pt;border-right-style:solid;border-right-width:1pt"><p class="s80" style="padding-left: 17pt;text-indent: 0pt;text-align: left;">NCT02697916</p></td></tr><tr style="height:11pt"><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:67pt"><p class="s80" style="padding-left: 8pt;padding-right: 6pt;text-indent: 0pt;text-align: center;">NCT01813435</p></td><td style="width:64pt"><p class="s80" style="padding-left: 7pt;padding-right: 9pt;text-indent: 0pt;text-align: center;">NCT02270242</p></td><td style="width:120pt;border-right-style:solid;border-right-width:1pt"><p class="s79" style="padding-top: 3pt;padding-left: 15pt;text-indent: 0pt;line-height: 6pt;text-align: left;">ANDAMAN</p></td></tr><tr style="height:13pt"><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:64pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:120pt;border-right-style:solid;border-right-width:1pt"><p class="s80" style="padding-left: 17pt;text-indent: 0pt;text-align: left;">NCT02520921</p></td></tr><tr style="height:16pt"><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s79" style="padding-left: 18pt;padding-right: 12pt;text-indent: 0pt;line-height: 6pt;text-align: center;">PRAGUE 18</p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s79" style="padding-left: 8pt;padding-right: 6pt;text-indent: 0pt;line-height: 6pt;text-align: center;">TREAT</p></td><td style="width:64pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s79" style="padding-left: 7pt;padding-right: 9pt;text-indent: 0pt;line-height: 6pt;text-align: center;">ISAR REACT 5</p></td><td style="width:120pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:13pt"><td style="width:67pt"><p class="s80" style="padding-left: 18pt;padding-right: 12pt;text-indent: 0pt;text-align: center;">NCT02808767</p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:67pt"><p class="s80" style="padding-left: 8pt;padding-right: 6pt;text-indent: 0pt;text-align: center;">NCT02298088</p></td><td style="width:64pt"><p class="s80" style="padding-left: 7pt;padding-right: 9pt;text-indent: 0pt;text-align: center;">NCT01944800</p></td><td style="width:120pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:16pt"><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s79" style="padding-left: 12pt;padding-right: 8pt;text-indent: 0pt;line-height: 6pt;text-align: center;">TOPIC</p></td><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s79" style="padding-left: 8pt;padding-right: 6pt;text-indent: 0pt;line-height: 6pt;text-align: center;">PHARMCLO</p></td><td style="width:64pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:120pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:11pt"><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p class="s80" style="padding-left: 12pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">NCT02099422</p></td><td style="width:67pt"><p class="s80" style="padding-left: 8pt;padding-right: 6pt;text-indent: 0pt;text-align: center;">NCT03347435</p></td><td style="width:64pt"><p class="s79" style="padding-top: 3pt;padding-left: 7pt;padding-right: 9pt;text-indent: 0pt;line-height: 6pt;text-align: center;">TAILOR PCI</p></td><td style="width:120pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:11pt"><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p class="s79" style="padding-top: 3pt;padding-left: 12pt;padding-right: 8pt;text-indent: 0pt;line-height: 6pt;text-align: center;">TROPICAL ACS</p></td><td style="width:67pt"><p class="s79" style="padding-top: 3pt;padding-left: 8pt;padding-right: 6pt;text-indent: 0pt;line-height: 6pt;text-align: center;">ADAPT</p></td><td style="width:64pt"><p class="s80" style="padding-left: 7pt;padding-right: 9pt;text-indent: 0pt;text-align: center;">NCT01742117</p></td><td style="width:120pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:13pt"><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p class="s80" style="padding-left: 12pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">NCT01959451</p></td><td style="width:67pt"><p class="s80" style="padding-left: 8pt;padding-right: 6pt;text-indent: 0pt;text-align: center;">NCT02508116</p></td><td style="width:64pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:120pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:15pt"><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s79" style="padding-left: 12pt;padding-right: 8pt;text-indent: 0pt;line-height: 6pt;text-align: center;">OPTIMA-C</p></td><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:64pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:120pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:9pt"><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p class="s80" style="padding-left: 12pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">NCT03056118</p></td><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:64pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:120pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:12pt"><td style="width:67pt"><p class="s79" style="padding-top: 5pt;padding-left: 18pt;padding-right: 12pt;text-indent: 0pt;line-height: 6pt;text-align: center;">IVUS-XPL</p></td><td style="width:62pt"><p class="s79" style="padding-top: 5pt;padding-left: 12pt;padding-right: 8pt;text-indent: 0pt;line-height: 6pt;text-align: center;">DAPT STEMI</p></td><td style="width:67pt"><p class="s79" style="padding-top: 5pt;padding-left: 8pt;padding-right: 6pt;text-indent: 0pt;line-height: 6pt;text-align: center;">SMART DATE</p></td><td style="width:64pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:120pt;border-right-style:solid;border-right-width:1pt"><p class="s79" style="padding-top: 5pt;padding-left: 10pt;text-indent: 0pt;line-height: 6pt;text-align: left;">MASTER DAPT</p></td></tr><tr style="height:9pt"><td style="width:67pt"><p class="s80" style="padding-left: 18pt;padding-right: 12pt;text-indent: 0pt;text-align: center;">NCT01308281</p></td><td style="width:62pt"><p class="s80" style="padding-left: 12pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">NCT01459627</p></td><td style="width:67pt"><p class="s80" style="padding-left: 8pt;padding-right: 6pt;text-indent: 0pt;text-align: center;">NCT01701453</p></td><td style="width:64pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:120pt;border-right-style:solid;border-right-width:1pt"><p class="s80" style="padding-left: 16pt;text-indent: 0pt;text-align: left;">NCT03023020</p></td></tr><tr style="height:12pt"><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p class="s79" style="padding-top: 5pt;padding-left: 12pt;padding-right: 8pt;text-indent: 0pt;line-height: 6pt;text-align: center;">REDUCE</p></td><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:64pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:120pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:13pt"><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p class="s80" style="padding-left: 12pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">NCT02118870</p></td><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:64pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:120pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:16pt"><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:64pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s81" style="padding-left: 7pt;padding-right: 9pt;text-indent: 0pt;line-height: 6pt;text-align: center;">AUGUSTUS</p></td><td style="width:120pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:11pt"><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p class="s79" style="padding-top: 3pt;padding-left: 12pt;padding-right: 8pt;text-indent: 0pt;line-height: 6pt;text-align: center;">REDUAL PCI</p></td><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:64pt"><p class="s82" style="padding-left: 7pt;padding-right: 9pt;text-indent: 0pt;text-align: center;">NCT03023020</p></td><td style="width:120pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:11pt"><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p class="s80" style="padding-left: 12pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">NCT02164864</p></td><td style="width:67pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:64pt"><p class="s81" style="padding-top: 3pt;padding-left: 7pt;padding-right: 9pt;text-indent: 0pt;line-height: 6pt;text-align: center;">ENTRUST AF PCI</p></td><td style="width:120pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:19pt"><td style="width:67pt;border-bottom-style:solid;border-bottom-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt;border-bottom-style:solid;border-bottom-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:67pt;border-bottom-style:solid;border-bottom-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:64pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s82" style="padding-left: 7pt;padding-right: 9pt;text-indent: 0pt;text-align: center;">NCT02866175</p></td><td style="width:120pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:36pt"><td style="width:496pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="6"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s36" style="padding-left: 11pt;padding-right: 15pt;text-indent: 0pt;line-height: 136%;text-align: left;">Published studies that are not currently referenced in the 2016 ACC/AHA or 2017 ESC DAPT focused updates are displayed with a <span class="s49">gray </span>background. Ongoing studies according to expected completion dates are shown with <span class="s49">colored </span><a href="#bookmark29" style=" color: black; font-family:&quot;Century Gothic&quot;, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt;">backgrounds. Abbreviations as in </a><a href="#bookmark29" class="s52">Figures 1</a><a href="#bookmark33" class="s52"> and </a><span class="s83">4</span>.</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="605" height="36" alt="image" src="j.jacc.2018.09.057/Image_020.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="76" height="53" alt="image" src="j.jacc.2018.09.057/Image_021.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="76" height="53" alt="image" src="j.jacc.2018.09.057/Image_022.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="467" height="106" alt="image" src="j.jacc.2018.09.057/Image_023.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="76" height="25" alt="image" src="j.jacc.2018.09.057/Image_024.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="608" height="91" alt="image" src="j.jacc.2018.09.057/Image_025.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="76" height="25" alt="image" src="j.jacc.2018.09.057/Image_026.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="76" height="53" alt="image" src="j.jacc.2018.09.057/Image_027.png"/></span></p><p class="s9" style="padding-top: 5pt;padding-left: 109pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a href="#bookmark75" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">therapy, goes beyond the scope of this section and is described elsewhere </a>(65,66)<span style=" color: #000;">.</span></p><p style="padding-top: 3pt;padding-left: 109pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><span class="s32">ASPIRIN DOSING. </span>The optimal dose of aspirin in pa- tients treated with DAPT, which is currently 81 mg (acceptable range between 75 and 100 mg) according to the 2016 ACC/AHA update and 75 to 100 mg ac- cording to the 2017 ESC update, is under further investigation. The ongoing ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Bene<span class="s28">ﬁ</span><a href="#bookmark76" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">ts and Long-term Effectiveness) trial is randomly assigning 20,000 subjects with established coronary artery dis- ease to either low-dose (81 mg) or high-dose (325 mg) aspirin </a><span style=" color: #007FAC;">(67)</span><a href="#bookmark77" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">. Results of investigations suggesting more favorable pharmacodynamics results with twice-daily administration of low-dose aspirin in patients with diabetes mellitus </a><span style=" color: #007FAC;">(68,69) </span>have also prompted clinical investigations in the <span class="s28">ﬁ</span>eld such as in the ongoing ANDAMAND (Aspirin Twice a Day  in Patients With Diabetes and Acute Coronary Syndrome) trial</p><p class="s9" style="padding-top: 5pt;padding-left: 9pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a href="https://www.clinicaltrials.gov/ct2/show/NCT02520921" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;" target="_blank">(</a>NCT02520921<a href="https://www.clinicaltrials.gov/ct2/show/NCT02270242" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;" target="_blank">). In addition, several trials of aspirin- free strategies (e.g., </a>NCT02270242<a href="https://www.clinicaltrials.gov/ct2/show/NCT03023020" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;" target="_blank">, </a>NCT03023020<span style=" color: #000;">) are ongoing that will clarify the net bene</span><span class="s28">ﬁ</span><a href="#bookmark78" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">t of using a single potent P2Y12 inhibitor (e.g., ticagrelor) for maintenance therapy after PCI </a>(70,71)<span style=" color: #000;">. The </span><span class="s28">ﬁ</span><a href="#bookmark79" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">rst trial in this series, named GLOBAL LEADERS, failed to show a difference in 2-year death or Q-wave myocardial infarction with the use of ticagrelor monotherapy (after 1 month of DAPT) compared with standard DAPT for 12 months followed by aspirin monotherapy for an additional 12 months </a>(72)<span style=" color: #000;">.</span></p><p class="s9" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><span class="s32">CHOICE OF P2Y12 INHIBITOR. </span><span style=" color: #000;">No differences in clinical ef</span><span class="s28">ﬁ</span><a href="#bookmark80" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">cacy and safety of prasugrel and ticagrelor were noted in a STEMI head-to-head comparison terminated early for futility </a>(73)<a href="#bookmark81" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">. Therefore, both op- tions remain valid with the same COR, while another head-to-head comparison between the 2 drugs in ACS is underway </a>(74)<span style=" color: #000;">. Most recently, the results of the TREAT (Ticagrelor in Patients With ST-Elevation</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:41.964pt" cellspacing="0"><tr style="height:18pt"><td style="width:424pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="3" bgcolor="#DEE9F7"><p class="s33" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="bookmark18">TABLE 4 </a><span class="s34">Major Differences Between the ACC/AHA and ESC Updates on DAPT</span><a name="bookmark35">&zwnj;</a></p></td></tr><tr style="height:13pt"><td style="width:112pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s35" style="padding-top: 3pt;padding-left: 48pt;padding-right: 47pt;text-indent: 0pt;text-align: center;">Topic</p></td><td style="width:139pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s35" style="padding-top: 3pt;padding-left: 38pt;padding-right: 37pt;text-indent: 0pt;text-align: center;">2016 ACC/AHA Update</p></td><td style="width:173pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s35" style="padding-top: 3pt;padding-left: 63pt;padding-right: 63pt;text-indent: 0pt;text-align: center;">2017 ESC Update</p></td></tr><tr style="height:19pt"><td style="width:112pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt" bgcolor="#DEE9F7"><p class="s36" style="padding-top: 1pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">Risk strati<span class="s37">ﬁ</span>cation</p></td><td style="width:139pt;border-top-style:solid;border-top-width:1pt" bgcolor="#DEE9F7"><p class="s36" style="padding-left: 17pt;padding-right: 19pt;text-indent: -10pt;line-height: 8pt;text-align: left;">DAPT score to assess the risk/bene<span class="s37">ﬁ</span>t of prolonging DAPT.</p></td><td style="width:173pt;border-top-style:solid;border-top-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DEE9F7"><p class="s36" style="padding-left: 15pt;padding-right: 41pt;text-indent: -9pt;line-height: 8pt;text-align: left;">Use of both DAPT and PRECISE-DAPT scores recommended.</p></td></tr><tr style="height:19pt"><td style="width:112pt;border-left-style:solid;border-left-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">Type of P2Y12 inhibitor in ACS</p></td><td style="width:139pt"><p class="s36" style="padding-left: 17pt;padding-right: 8pt;text-indent: -10pt;line-height: 8pt;text-align: left;">Class IIa recommendation for ticagrelor or prasugrel preferred to clopidogrel.</p></td><td style="width:173pt;border-right-style:solid;border-right-width:1pt"><p class="s36" style="padding-left: 15pt;padding-right: 25pt;text-indent: -9pt;line-height: 8pt;text-align: left;">Class I recommendation for ticagrelor or prasugrel preferred to clopidogrel.</p></td></tr><tr style="height:51pt"><td style="width:112pt;border-left-style:solid;border-left-width:1pt" bgcolor="#DEE9F7"><p class="s36" style="padding-top: 1pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">Timing of P2Y12 inhibitor</p></td><td style="width:139pt" bgcolor="#DEE9F7"><p class="s36" style="padding-top: 1pt;padding-left: 17pt;padding-right: 7pt;text-indent: -10pt;line-height: 108%;text-align: justify;">Does not include updated recommendations or revision of existing recommendations from previous guidelines.</p></td><td style="width:173pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DEE9F7"><p class="s36" style="padding-top: 1pt;padding-left: 15pt;padding-right: 5pt;text-indent: -9pt;line-height: 108%;text-align: left;">Focused update with recommendations on early use of ticagrelor or clopidogrel for non<span class="s39">–</span>ST-segment elevation ACS undergoing invasive management and option to pre-treat with ticagrelor or prasugrel in patients at high ischemic risk and low bleeding risk undergoing elective PCI.</p></td></tr><tr style="height:35pt"><td style="width:112pt;border-left-style:solid;border-left-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">Switching of P2Y12 inhibitors</p></td><td style="width:139pt"><p class="s36" style="padding-top: 1pt;padding-left: 17pt;padding-right: 7pt;text-indent: -10pt;line-height: 108%;text-align: justify;">Does not include updated recommendations or revision of existing recommendations from previous guidelines.</p></td><td style="width:173pt;border-right-style:solid;border-right-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 15pt;padding-right: 5pt;text-indent: -9pt;line-height: 108%;text-align: left;">Covered in detail with recommendations on early upgrading from clopidogrel to ticagrelor in ACS and switching between P2Y12 inhibitors once side effects or drug intolerance occurs.</p></td></tr><tr style="height:35pt"><td style="width:112pt;border-left-style:solid;border-left-width:1pt" bgcolor="#DEE9F7"><p class="s36" style="padding-top: 1pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">Proton pump inhibitors</p></td><td style="width:139pt" bgcolor="#DEE9F7"><p class="s36" style="padding-top: 1pt;padding-left: 17pt;padding-right: 3pt;text-indent: -10pt;line-height: 108%;text-align: left;">Class I in patients on DAPT with a history of gastrointestinal bleeding and those at increased risk of gastrointestinal bleeding.</p></td><td style="width:173pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DEE9F7"><p class="s36" style="padding-top: 1pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">Class I in patients on DAPT.</p></td></tr><tr style="height:35pt"><td style="width:112pt;border-left-style:solid;border-left-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 16pt;text-indent: -10pt;line-height: 109%;text-align: left;">DAPT duration after PCI for stable coronary artery disease</p></td><td style="width:139pt"><p class="s36" style="padding-top: 1pt;padding-left: 17pt;padding-right: 17pt;text-indent: -10pt;line-height: 109%;text-align: justify;">Default DAPT duration is 6 months after drug-eluting stent and 1 month after bare-metal stent implantation.</p></td><td style="width:173pt;border-right-style:solid;border-right-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 15pt;padding-right: 5pt;text-indent: -9pt;line-height: 108%;text-align: left;">Default DAPT duration is 6 months regardless of stent type. A 1-month course of DAPT may be considered in selected patients treated with drug-eluting stents and at high bleeding risk.</p></td></tr><tr style="height:27pt"><td style="width:112pt;border-left-style:solid;border-left-width:1pt" bgcolor="#DEE9F7"><p class="s36" style="padding-top: 1pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">DAPT duration after PCI for ACS</p></td><td style="width:139pt" bgcolor="#DEE9F7"><p class="s36" style="padding-top: 1pt;padding-left: 17pt;padding-right: 2pt;text-indent: -10pt;line-height: 109%;text-align: left;">Extended therapy recommended as Class IIb for selected patients at low bleeding risk.</p></td><td style="width:173pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DEE9F7"><p class="s36" style="padding-left: 15pt;padding-right: 9pt;text-indent: -9pt;line-height: 8pt;text-align: left;">Extended therapy, preferentially with ticagrelor, recommended as Class IIb for selected patients with prior myocardial infarction.</p></td></tr><tr style="height:27pt"><td style="width:112pt;border-left-style:solid;border-left-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 16pt;padding-right: 6pt;text-indent: -10pt;line-height: 108%;text-align: left;">DAPT duration in patients undergoing CABG</p></td><td style="width:139pt"><p class="s36" style="padding-top: 1pt;padding-left: 17pt;padding-right: 7pt;text-indent: -10pt;line-height: 108%;text-align: justify;">Does not include updated recommendations or revision of existing recommendations from previous guidelines.</p></td><td style="width:173pt;border-right-style:solid;border-right-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">Includes an updated dedicated section.</p></td></tr><tr style="height:19pt"><td style="width:112pt;border-left-style:solid;border-left-width:1pt" bgcolor="#DEE9F7"><p class="s36" style="padding-left: 16pt;text-indent: -10pt;line-height: 8pt;text-align: left;">DAPT duration in patients with ACS medically managed</p></td><td style="width:139pt" bgcolor="#DEE9F7"><p class="s36" style="padding-left: 17pt;padding-right: 19pt;text-indent: -10pt;line-height: 8pt;text-align: left;">Class IIa for ticagrelor in preference to clopidogrel for 12 months.</p></td><td style="width:173pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DEE9F7"><p class="s36" style="padding-left: 15pt;padding-right: 16pt;text-indent: -9pt;line-height: 8pt;text-align: left;">Class I for ticagrelor in preference to clopidogrel for 12 months.</p></td></tr><tr style="height:51pt"><td style="width:112pt;border-left-style:solid;border-left-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 16pt;text-indent: -10pt;line-height: 109%;text-align: left;">DAPT in patients undergoing noncardiac surgery</p></td><td style="width:139pt"><p class="s36" style="padding-top: 1pt;padding-left: 17pt;padding-right: 11pt;text-indent: -10pt;line-height: 108%;text-align: left;">Surgery must be delayed 1 month after implantation of bare-metal stents and 6 months after implantation of DES (Class I).</p></td><td style="width:173pt;border-right-style:solid;border-right-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 15pt;padding-right: 5pt;text-indent: -9pt;line-height: 109%;text-align: left;">Surgery should occur no sooner than 1 month irrespective of the stent type (Class IIa) and no sooner than</p><p class="s36" style="padding-left: 15pt;padding-right: 4pt;text-indent: 0pt;line-height: 108%;text-align: left;">6 months in case of recent MI or other high ischemic risk features (Class IIb). Option for bridging strategy with intravenous antiplatelet agents in selected patients (Class IIb).</p></td></tr><tr style="height:27pt"><td style="width:112pt;border-left-style:solid;border-left-width:1pt" bgcolor="#DEE9F7"><p class="s36" style="padding-top: 1pt;padding-left: 16pt;padding-right: 6pt;text-indent: -10pt;line-height: 109%;text-align: left;">Antiplatelet therapy in patients on oral anticoagulation</p></td><td style="width:139pt" bgcolor="#DEE9F7"><p class="s36" style="padding-top: 1pt;padding-left: 17pt;padding-right: 7pt;text-indent: -10pt;line-height: 108%;text-align: justify;">Does not include updated recommendations or revision of existing recommendations from previous guidelines.</p></td><td style="width:173pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DEE9F7"><p class="s36" style="padding-top: 1pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">Includes an updated dedicated section.</p></td></tr><tr style="height:31pt"><td style="width:112pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 16pt;padding-right: 6pt;text-indent: -10pt;line-height: 108%;text-align: left;">Companion document with clinical vignettes illustrating DAPT scenarios in the real-life setting</p></td><td style="width:139pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 38pt;padding-right: 37pt;text-indent: 0pt;text-align: center;">No.</p></td><td style="width:173pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s36" style="padding-top: 1pt;padding-left: 63pt;padding-right: 63pt;text-indent: 0pt;text-align: center;">Yes.</p></td></tr><tr style="height:29pt"><td style="width:424pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="3"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s41" style="padding-left: 6pt;padding-right: 5pt;text-indent: 0pt;line-height: 122%;text-align: left;">ACS <span class="s42">¼ </span>acute coronary syndromes; DAPT <span class="s42">¼ </span>dual antiplatelet therapy; PCI <span class="s42">¼ </span>percutaneous coronary intervention; PRECISE-DAPT <span class="s42">¼ </span>Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy.</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 41pt;text-indent: 0pt;line-height: 140%;text-align: justify;">Myocardial Infarction Treated With Pharmacological Thrombolysis) trial showed that, in patients younger than age 75 years presenting with STEMI, adminis- tration of ticagrelor after <span class="s28">ﬁ</span><a href="#bookmark82" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">brinolytic therapy was noninferior to clopidogrel on 30-day major bleeding events, with no differences in ischemic events </a><span style=" color: #007FAC;">(75)</span>. However, a critical aspect that remains unanswered and not addressed in this trial is the effect of tica- grelor administration concomitant to <span class="s28">ﬁ</span>brinolytic therapy given that timing of administration of oral P2Y12 inhibiting therapy typically occurred within</p><p style="padding-left: 41pt;text-indent: 0pt;line-height: 9pt;text-align: justify;">11.5 h post-<span class="s28">ﬁ</span>brinolysis.</p><p class="s32" style="padding-top: 4pt;padding-left: 41pt;text-indent: 0pt;text-align: justify;">SWITCHING, DE-ESCALATION, PLATELET FUNCTION</p><p class="s32" style="padding-top: 3pt;padding-left: 41pt;text-indent: 0pt;line-height: 140%;text-align: justify;">TESTING, AND GENOTYPING. <span class="p">With respect to switching, a recent international document from American and European experts covering the topic in detail has</span></p><p style="padding-top: 5pt;padding-left: 9pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a href="#bookmark55" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">been recently released, with practical recommenda- tions mostly based on consensus and pharmacody- namic investigations </a><span style=" color: #007FAC;">(27)</span><a href="#bookmark83" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">. A number of studies have investigated the clinical impact of switching thera- pies. In the TOPIC (Timing Of Platelet Inhibition after acute Coronary Syndrome) trial, bleeds were reduced by de-escalating from the more potent P2Y12 in- hibitors prasugrel or ticagrelor to clopidogrel at 30 days after PCI for an ACS </a><span style=" color: #007FAC;">(76)</span>. However, the study was of limited sample size and not powered for ef<span class="s28">ﬁ</span>- cacy. Building on the same principle of <span class="s11">“</span>de-escala- tion,<span class="s11">” </span>the TROPICAL ACS trial suggested that de- escalation of antiplatelet treatment (e.g., from pra- sugrel to clopidogrel in patients with normal clopi- dogrel platelet inhibition response) guided by platelet function testing is noninferior to standard treatment</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s9" style="padding-top: 5pt;padding-left: 109pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a href="#bookmark84" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;" name="bookmark19">with prasugrel at 1 year </a>(77)<a href="#bookmark85" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">. Recently, in the PHARMCLO (Pharmacogenomic Approach to Select- ing Antiplatelet Therapy in Acute Coronary Syn- dromes) trial, genotyping to inform selection of antiplatelet therapy improved outcomes in patients with NSTE-ACS or STEMI compared with the standard of care </a>(78)<a href="#bookmark86" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">. However, the results of this trial need to be interpreted with caution as it was terminated prematurely, potentially overestimating the effect size </a>(79)<a href="#bookmark87" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">. A number of ongoing randomized studies using genetic testing are currently ongoing </a>(80)<span style=" color: #000;">. The results of these studies may have an effect on future guideline recommendations on the use of genetic testing.</span><a name="bookmark20">&zwnj;</a><a name="bookmark21">&zwnj;</a></p><p style="padding-top: 6pt;padding-left: 109pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><span class="s32">DAPT DURATION. </span><a href="#bookmark60" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">A number of PCI trials of DAPT duration were unpublished at the time when meta- analyses informing current documents were con- ducted </a><span style=" color: #007FAC;">(39,40) </span><a href="#bookmark31" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">(</a><span class="s30">Table 3</span>). Their contribution to the overall evidence is likely minimal or con<span class="s28">ﬁ</span>rmatory. A patient-level meta-analysis of 6 DAPT duration trials identi<span class="s28">ﬁ</span>ed PCI complexity as a potential treatment modi<span class="s28">ﬁ</span><a href="#bookmark88" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">er when comparing longer and shorter DAPT regimens </a><span style=" color: #007FAC;">(81)</span>. This issue was not covered by both the ACC/AHA and ESC updates. In addition, 2 ACS trials of DAPT duration were presented at the Transcatheter Cardiovascular Therapeutics meeting in 2017, which are unpublished at the time of drafting this article. The DAPT-STEMI (Randomized, Open Label Trial of 6 Months Versus 12 Months DAPT After Drug-Eluting Stent in STEMI) trial met the primary hypothesis of 6-month DAPT being noninferior to 12-month DAPT with respect to a composite of ischemic and bleeding outcomes, but the observed rate of events was lower than anticipated. A power issue was even more pro- nounced in the REDUCE (Short-term Dual Anti Platelet Therapy in Patients With ACS Treated With the COMBO Dual-therapy Stent) trial, where the in- vestigators compared 3-month DAPT versus 12-month DAPT in patients with ACS. Again, the noninferiority hypothesis was met, but the margin of noninferiority was large, and the direction of the estimates for some important ischemic endpoints disfavored the 3- month DAPT group. A third published trial, named SMART-DATE (Safety of 6-month Duration of Dual Antiplatelet Therapy After Acute Coronary Syn- dromes) (N <span class="s11">¼ </span><a href="#bookmark89" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">2,172), also recently met the hypothesis of shorter DAPT (6 months) being noninferior to 12- month DAPT in ACS, but also showed an increased risk of MI with shorter duration, concluding that prolonged DAPT should remain the standard of care in patients with ACS undergoing PCI </a><span style=" color: #007FAC;">(82)</span>.</p><p style="text-indent: 0pt;line-height: 8pt;text-align: right;">Overall, the newly available data seem to support</p><p style="padding-top: 3pt;text-indent: 0pt;text-align: right;">current recommendations. Following the results of</p><p class="s9" style="padding-top: 5pt;padding-left: 9pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a href="#bookmark90" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">the ZEUS (Zotarolimus-Eluting Endeavor Sprint Stent in Uncertain DES Candidates) </a>(83,84)<a href="#bookmark91" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">, LEADERS- FREE (Prospective Randomized Comparison of the BioFreedom Biolimus A9 Drug-Coated Stent versus the Gazelle Bare-Metal Stent in Patients at High Bleeding Risk) </a>(85)<a href="#bookmark92" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">, and SENIOR (Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percuta- neous Coronary Revascularization) </a>(86) <a href="https://www.clinicaltrials.gov/ct2/show/NCT03023020" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;" target="_blank">trials, showing that drug-eluting stents outperform bare- metal stents in high bleeding risk candidates on a 1-month term of DAPT, a number of additional trials of very short DAPT for patients at high risk of bleeding are ongoing (</a>NCT03023020<a href="https://www.clinicaltrials.gov/ct2/show/NCT03344653" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;" target="_blank">; </a>NCT03344653<a href="https://www.clinicaltrials.gov/ct2/show/NCT03218787" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;" target="_blank">; </a>NCT03218787<a href="https://www.clinicaltrials.gov/ct2/show/NCT02594501" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;" target="_blank">; </a>NCT02594501<span style=" color: #000;">). Risk strati</span><span class="s28">ﬁ</span><span style=" color: #000;">cation tools, such as the DAPT score and the PRECISE-DAPT score, are useful companions in daily practice but more research in this </span><span class="s28">ﬁ</span><a href="#bookmark93" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">eld is necessary, because prospective validation is lacking and the discrimi- nation ability in retrospective validation studies is at best moderate-to-good </a>(87)<span style=" color: #000;">.</span></p><p class="s32" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;text-align: justify;">ANTIPLATELET THERAPY IN PATIENTS ON ORAL</p><p class="s9" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><span class="s32">ANTICOAGULANTS. </span><span style=" color: #000;">In patients with atrial </span><span class="s28">ﬁ</span><a href="#bookmark73" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">brilla- tion who had undergone PCI, the RE-DUAL PCI trial showed that at a mean of 14 months the risk of major or clinically relevant nonmajor bleeding was lower using a dual-therapy regimen with dabigatran (110 or 150 mg twice daily) plus a P2Y12 inhibitor (clopidogrel or ticagrelor) compared with those who received tri- ple therapy with warfarin, a P2Y12 inhibitor, and aspirin for 1 or 3 months according to stent type </a>(63)<span style=" color: #000;">. Overall, dual therapy was noninferior to triple ther- apy with respect to the risk of thromboembolic events. Other ongoing studies testing antithrombotic strategies in atrial </span><span class="s28">ﬁ</span><a href="#bookmark94" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">brillation patients undergoing PCI, including strategies with the use of apixaban </a>(88) <a href="#bookmark95" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">and edoxaban </a>(89)<span style=" color: #000;">, are currently ongoing.</span></p><p class="s32" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 144%;text-align: justify;">ANTIPLATELET THERAPY IN PATIENTS UNDERGOING CARDIAC AND NON-CARDIAC SURGERY. <span class="p">A number of</span></p><p class="s9" style="padding-left: 9pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a href="#bookmark96" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">national societies have developed algorithms based on multidisciplinary collaborative efforts providing guidance on how to manage antiplatelet therapy in patients undergoing surgery </a><a href="#bookmark96" class="s8">(90</a><a href="#bookmark96" class="s14">–</a>92)<span style=" color: #000;">. Even so, several other questions remain on DAPT in cardiac surgery, including whether and for how long DAPT should be restarted in CABG patients with stable CAD, and the timing for reinitiation in ACS patients. Other unsolved issues in the CABG setting regard the timing of discontinuation for different P2Y12 inhibitors, the optimal use of platelet function testing while awaiting surgery, and how to manage perioperative bleeding complications caused by DAPT.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s31" style="padding-top: 5pt;padding-left: 41pt;text-indent: 0pt;text-align: left;"><a name="bookmark22">CONCLUSIONS</a><a name="bookmark23">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 41pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="136" height="0" alt="image" src="j.jacc.2018.09.057/Image_028.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 41pt;text-indent: 0pt;line-height: 139%;text-align: justify;">The rapid evolution of the <span class="s28">ﬁ</span>eld of antithrombotic pharmacotherapy, in an ever-changing landscape of safer stents, bleeding avoidance strategies, and newer drugs for secondary prevention, requires reg- ular updates of recommendations for DAPT. Indeed, the risk-bene<span class="s28">ﬁ</span>t of DAPT depends on many individual circumstances, including the clinical scenario and the susceptibility to ischemia, bleeding, or both. The current ACC/AHA and ESC updates for DAPT are substantially similar with respect to key recommen- dations on P2Y12 inhibitor selection and DAPT dura- tion. However, whereas the 2016 ACC/AHA update is essentially centered around the topic of DAPT dura- tion, the ESC document has a broader focus on anti- platelet therapy in general and relative to speci<span class="s28">ﬁ</span><a href="#bookmark35" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;">c clinical scenarios (</a><span class="s30">Table 4</span>). Nevertheless, a common and important theme in both updates is the shift from</p><p style="padding-top: 5pt;padding-left: 9pt;text-indent: 0pt;line-height: 140%;text-align: justify;">a population-based treatment approach to one that is more <span class="s11">“</span>patient-centered.<span class="s11">” </span>Indeed, this is a step to- ward an emerging approach for disease treatment and prevention called <span class="s11">“</span>precision medicine,<span class="s11">” </span>which takes into account individual variability in genes, envi- ronment, and lifestyle for each person. Although the evidence generated since the publication of the ACC/ AHA and ESC updates seems unlikely to provoke breakthrough changes with respect to existing rec- ommendations, ongoing studies will de<span class="s28">ﬁ</span>ne new areas of interest and possibly lead to modi<span class="s28">ﬁ</span>cations in future recommendations to better personalize patient care.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 9pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="277" height="0" alt="image" src="j.jacc.2018.09.057/Image_029.png"/></span></p><p class="s32" style="padding-top: 5pt;padding-left: 9pt;text-indent: 0pt;text-align: justify;">ADDRESS FOR CORRESPONDENCE: <span class="p">Dr. Dominick J.</span></p><p class="s9" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 140%;text-align: justify;"><a href="mailto:dominick.angiolillo@jax.ufl.edu" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;" target="_blank">Angiolillo, University of Florida College of Medicine- Jacksonville, 655 West 8th Street, Jacksonville, Flor- ida 32209. E-mail: </a>dominick.angiolillo@jax.u<a href="mailto:dominick.angiolillo@jax.ufl.edu" style=" color: #007FAC; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;" target="_blank">ﬂ</a>.edu<a href="https://twitter.com/UFHealthJax" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;" target="_blank">. Twitter: </a>@UFHealthJax<a href="https://twitter.com/UFMedicine" style=" color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7.5pt;" target="_blank">, </a>@UFMedicine<span style=" color: #000;">.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 41pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="561" height="0" alt="image" src="j.jacc.2018.09.057/Image_030.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s25" style="padding-top: 4pt;padding-left: 41pt;text-indent: 0pt;text-align: left;">RE FE RE NCE S</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ol id="l17"><li><p class="s89" style="padding-left: 41pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref1" class="a" target="_blank" name="bookmark36">Angiolillo DJ. The evolution of antiplatelet therapy in the treatment of acute coronary syn- dromes. Drugs 2012;72:2087</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref1" class="s85" target="_blank">–</a>116<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 4pt;padding-left: 41pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref2" class="a" target="_blank" name="bookmark37">Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Car- diol 2015;12:30</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref2" class="s85" target="_blank">–</a>47<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 4pt;padding-left: 41pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref3" class="a" target="_blank">Franchi F, Rollini F, Angiolillo DJ. Antith- rombotic therapy for patients with STEMI under- going primary PCI. Nat Rev Cardiol 2017;14: 361</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref3" class="s85" target="_blank">–</a>79<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 4pt;padding-left: 41pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref4" class="a" target="_blank" name="bookmark38">Moon JY,  Franchi  F,  Rollini  F, Angiolillo DJ. Evolution of coronary stent technology and im- plications for duration of dual antiplatelet therapy. Prog Cardiovasc Dis 2018;60:478</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref4" class="s85" target="_blank">–</a>90<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 4pt;padding-left: 41pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref5" class="a" target="_blank" name="bookmark39">Moon JY, Franchi F, Rollini F, Angiolillo DJ. The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts. Expert Rev Hem- atol 2018;11:5</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref5" class="s85" target="_blank">–</a>12<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 4pt;padding-left: 41pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref6" class="a" target="_blank" name="bookmark40">Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/ AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary ar- tery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016;68:1082</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref6" class="s85" target="_blank">–</a>115<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 4pt;padding-left: 41pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref7" class="a" target="_blank" name="bookmark41">Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J 2018;39:213</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref7" class="s85" target="_blank">–</a>60<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 4pt;padding-left: 41pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref8" class="a" target="_blank" name="bookmark42">Neumann F-J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revas- cularization. Eur Heart J 2018 Aug 25 [E-pub ahead of </a>print]<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 4pt;padding-left: 41pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref9" class="a" target="_blank">Mauri L, Kereiakes DJ, Yeh RW, et al. [DAPT] twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371: 2155</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref9" class="s85" target="_blank">–</a>66<span style=" color: #000;">.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p class="s89" style="padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref10" class="a" target="_blank" name="bookmark43">Yeh RW, Secemsky EA, Kereiakes DJ, et al. Development and validation of a prediction rule for </a>bene<a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref10" class="s88" target="_blank">ﬁ</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref10" class="a" target="_blank">t and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary inter- vention. JAMA 2016;315:1735</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref10" class="s85" target="_blank">–</a>49<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref11" class="a" target="_blank" name="bookmark44">Costa F, van Klaveren D, James S, et al. Deri- vation and validation of the predicting bleeding complications in patients undergoing stent im- plantation and subsequent dual antiplatelet ther- apy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017;389:1025</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref11" class="s85" target="_blank">–</a>34<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref12" class="a" target="_blank" name="bookmark45">Wallentin L, Becker RC, Budaj A, et al. Tica- grelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl  J Med  2009;361: 1045</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref12" class="s85" target="_blank">–</a>57<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref13" class="a" target="_blank" name="bookmark46">Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357: 2001</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref13" class="s85" target="_blank">–</a>15<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref14" class="a" target="_blank" name="bookmark47">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;64: 2645</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref14" class="s85" target="_blank">–</a>87<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref15" class="a" target="_blank" name="bookmark48">O</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref15" class="s85" target="_blank">’</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref15" class="a" target="_blank">Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61:485</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref15" class="s85" target="_blank">–</a>510<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref16" class="a" target="_blank" name="bookmark49">Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013;369:999</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref16" class="s85" target="_blank">–</a>1010<span style=" color: #000;">.</span></p></li><li><p style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref17" class="a" target="_blank" name="bookmark50">Rof</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref17" class="s88" target="_blank">ﬁ </a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref17" class="a" target="_blank">M, Patrono C, Collet J-P, et al. 2015 ESC guidelines for the management of acute </a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref17" target="_blank">coronary</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s89" style="padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref17" class="a" target="_blank">syndromes in patients presenting without persis- tent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST- Segment Elevation of. Eur Heart J 2016;37: 267</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref17" class="s85" target="_blank">–</a>315<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref18" class="a" target="_blank">Capodanno D, Angiolillo DJ. Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guide- lines. Circ Cardiovasc Interv </a>2015;8:e002301<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref19" class="a" target="_blank" name="bookmark51">Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocar- dial infarction in patients presenting with ST- segment elevation. Eur Heart J 2018;39:119</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref19" class="s85" target="_blank">–</a>77<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref20" class="a" target="_blank" name="bookmark52">Collet J-P, Cuisset T, Rangé G, et al. Bedside monitoring to adjust antiplatelet therapy for cor- onary stenting. N Engl J Med 2012;367:2100</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref20" class="s85" target="_blank">–</a>9<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref21" class="a" target="_blank">Trenk D, Stone GW, Gawaz M, et al. A Randomized Trial of prasugrel versus clopidog- rel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents. J Am Coll Cardiol 2012;59:2159</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref21" class="s85" target="_blank">–</a>64<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref22" class="a" target="_blank">Price MJ, Berger PB, Teirstein PS, et al. Stan- dard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention. JAMA </a>2011;305:1097<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref23" class="a" target="_blank">Cayla G, Cuisset T, Silvain J, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded- endpoint, randomised controlled superiority trial. Lancet 2016;388:2015</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref23" class="s85" target="_blank">–</a>22<span style=" color: #000;">.</span></p></li><li><p style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="https://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm203888.htm" style=" color: black; font-family:&quot;Century Gothic&quot;, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt;" target="_blank" name="bookmark53">U.S. Food and Drug Administration. FDA Drug Safety Communication: reduced effec- tiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. Avail- able at: </a><a href="https://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm203888.htm" target="_blank">https://www.fda.gov/drugs/drugsafety/</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s89" style="padding-top: 5pt;padding-left: 109pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="https://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm203888.htm" class="a" target="_blank">postmarketdrugsafetyinformationforpatientsand </a>providers/ucm203888.htm<span style=" color: #000;">. Accessed October 16, 2018.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 109pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref25" class="a" target="_blank">Simon T, Bhatt DL, Bergougnan L, et al. Ge- netic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects. Clin Pharmacol Ther 2011;90:287</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref25" class="s85" target="_blank">–</a>95<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 109pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref26" class="a" target="_blank" name="bookmark54">Wallentin L, Becker RC, Budaj A, et al. Tica- grelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361: 1045</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref26" class="s85" target="_blank">–</a>57<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 109pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref27" class="a" target="_blank" name="bookmark55">Angiolillo DJ, Rollini F, Storey RF, et al. In- ternational expert consensus on switching platelet P2Y12 receptor</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref27" class="s85" target="_blank">–</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref27" class="a" target="_blank">inhibiting therapies. Circulation 2017;136:1955</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref27" class="s85" target="_blank">–</a>75<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 109pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref28" class="a" target="_blank">Rollini F, Franchi F, Angiolillo DJ. Switching P2Y12-receptor inhibitors in patients with coro- nary artery disease. Nat Rev Cardiol 2016;13:11</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref28" class="s85" target="_blank">–</a>27<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 109pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref29" class="a" target="_blank" name="bookmark56">Angiolillo DJ, Gibson CM, Cheng S, et al. Dif- ferential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 2011;89:65</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref29" class="s85" target="_blank">–</a>74<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 109pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020839s055lbl.pdf" style=" color: black; font-family:&quot;Century Gothic&quot;, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt;" target="_blank">Plavix. Highlights of prescribing informa- tion. Available at: </a><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020839s055lbl.pdf" class="a" target="_blank">https://www.accessdata.fda. gov/drugsatfda_docs/label/2011/020839s055lbl.</a> pdf<span style=" color: #000;">. Accessed October 16, 2018.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 109pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref31" class="a" target="_blank" name="bookmark57">Bhatt DL, Cryer BL, Contant CF, et al. Clopi- dogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref31" class="s85" target="_blank">–</a>17<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 109pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref32" class="a" target="_blank" name="bookmark58">Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011;58:2550</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref32" class="s85" target="_blank">–</a>83<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 109pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref33" class="a" target="_blank" name="bookmark59">Kim B-K, Hong M-K, Shin D-H, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and </a>Ef<a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref33" class="s88" target="_blank">ﬁ</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref33" class="a" target="_blank">cacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012;60:1340</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref33" class="s85" target="_blank">–</a>8<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 109pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref34" class="a" target="_blank">Feres F, Costa RA, Abizaid A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents. JAMA 2013;310: 2510</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref34" class="s85" target="_blank">–</a>22<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 109pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref35" class="a" target="_blank">Gwon H-C, Hahn J-Y, Park KW, et al. Six- month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the </a>Ef- <a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref35" class="s88" target="_blank">ﬁ</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref35" class="a" target="_blank">cacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Random- ized, Multicenter Study. Circulation 2012;125: 505</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref35" class="s85" target="_blank">–</a>13<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 109pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref36" class="a" target="_blank">Colombo A, Chieffo A, Frasheri A, et al. Sec- ond-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy. J Am Coll Cardiol 2014;64:2086</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref36" class="s85" target="_blank">–</a>97<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 109pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref37" class="a" target="_blank">Schulz-Schüpke S, Byrne RA, Ten Berg JM, et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 2015;36:1252</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref37" class="s85" target="_blank">–</a>63<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 5pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref38" class="a" target="_blank">Han Y, Xu B, Xu K, et al. Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 Trial. Circ Cardiovasc Interv </a>2016;9:e003145<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref39" class="a" target="_blank" name="bookmark60">Hong S-J, Shin D-H, Kim J-S, et al. 6-month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implan- tation. J Am Coll Cardiol Intv 2016;9:1438</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref39" class="s85" target="_blank">–</a>46<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref40" class="a" target="_blank">Lee B-K, Kim J-S, Lee O-H, et al. Safety of six- month dual antiplatelet therapy after second- generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy. EuroIntervention 2018;13:1923</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref40" class="s85" target="_blank">–</a>30<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref41" class="a" target="_blank" name="bookmark61">Nakamura M, Iijima R, Ako J, et al. Dual anti- platelet therapy for 6 versus 18 months after biodegradable polymer drug-eluting stent im- plantation. J Am Coll Cardiol Intv 2017;10: 1189</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref41" class="s85" target="_blank">–</a>98<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref42" class="a" target="_blank">Valgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012;125:2015</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref42" class="s85" target="_blank">–</a>26<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref43" class="a" target="_blank">Didier R, Morice MC, Barragan P, et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin. J Am Coll Cardiol Intv 2017;10:1202</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref43" class="s85" target="_blank">–</a>10<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref44" class="a" target="_blank">Collet J-P, Silvain J, Barthélémy O, et al. Dual- antiplatelet treatment beyond 1 year after drug- eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet 2014;384:1577</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref44" class="s85" target="_blank">–</a>85<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref45" class="a" target="_blank">Lee CW, Ahn J-M, Park D-W, et al. Optimal duration of dual antiplatelet therapy after drug- eluting stent implantation: a randomized, controlled trial. Circulation 2014;129:304</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref45" class="s85" target="_blank">–</a>12<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref46" class="a" target="_blank">Helft G, Steg PG, Le Feuvre C, et al. Stopping or continuing clopidogrel 12 months after drug- eluting stent placement: the OPTIDUAL random- ized trial. Eur Heart J 2016;37:365</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref46" class="s85" target="_blank">–</a>74<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref47" class="a" target="_blank" name="bookmark62">Bittl JA, Baber U, Bradley SM, Wijeysundera DN. Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC/ AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coro- nary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016;68:1116</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref47" class="s85" target="_blank">–</a>39<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref48" class="a" target="_blank" name="bookmark63">Palmerini T, Benedetto U, Bacchi-Reggiani L, et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug- eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 2015;385:2371</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref48" class="s85" target="_blank">–</a>82<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref49" class="a" target="_blank">Navarese EP, Andreotti F, Schulze V, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ </a>2015;350:h1618<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref50" class="a" target="_blank">Giustino G, Baber U, Sartori S, et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation. J Am Coll Cardiol 2015;65: 1298</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref50" class="s85" target="_blank">–</a>310<span style=" color: #000;">.</span></p></li><li><p style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref51" class="a" target="_blank" name="bookmark64">Alfonso F, Jiménez-Borreguero LJ. Optimizing dual antiplatelet therapy duration after </a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref51" target="_blank">myocardial</a></p><p class="s89" style="padding-top: 5pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref51" class="a" target="_blank">infarction: evidence-based, precision, or person- alized medicine? Eur Heart J 2017;38:1056</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref51" class="s85" target="_blank">–</a>9<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref52" class="a" target="_blank" name="bookmark65">Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref52" class="s85" target="_blank">–</a>502<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref53" class="a" target="_blank" name="bookmark66">Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin fol- lowed by long-term therapy in patients undergo- ing percutaneous coronary intervention: the PCI- CURE study. Lancet 2001;358:527</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref53" class="s85" target="_blank">–</a>33<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref54" class="a" target="_blank" name="bookmark67">Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Associa- tion Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anes- thesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011;58:e123</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref54" class="s85" target="_blank">–</a>210<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref55" class="a" target="_blank" name="bookmark68">Bonaca MP, Bhatt DL, Cohen M, et al. Long- term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372: 1791</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref55" class="s85" target="_blank">–</a>800<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref56" class="a" target="_blank" name="bookmark69">Investigators TC  in UA to  PRET.  Effects  of Clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref56" class="s85" target="_blank">–</a>502<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref57" class="a" target="_blank" name="bookmark70">Roe MT, Armstrong PW, Fox KAA, et al. Pra- sugrel versus clopidogrel for acute coronary syn- dromes without revascularization. N Engl J Med 2012;367:1297</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref57" class="s85" target="_blank">–</a>309<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref58" class="a" target="_blank" name="bookmark71">Angiolillo DJ, Goodman SG, Bhatt DL, et al. Antithrombotic Therapy in patients with </a>atrial <a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref58" class="s88" target="_blank">ﬁ</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref58" class="a" target="_blank">brillation undergoing percutaneous coronary intervention: a North American perspective</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref58" class="s85" target="_blank">—</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref58" class="a" target="_blank">2016 update. Circ Cardiovasc Interv </a>2016;9:e004395<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref59" class="a" target="_blank">Angiolillo DJ, Goodman SG, Bhatt DL, et al. Antithrombotic therapy in patients with atrial </a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref59" class="s88" target="_blank">ﬁ</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref59" class="a" target="_blank">brillation treated with oral anticoagulation un- dergoing percutaneous coronary intervention: a North American perspective</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref59" class="s85" target="_blank">—</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref59" class="a" target="_blank">2018 update. Circu- lation 2018;138:527</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref59" class="s85" target="_blank">–</a>36<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref60" class="a" target="_blank" name="bookmark72">Dewilde WJM, Oirbans T, Verheugt FWA, et al. Use of clopidogrel with or without aspirin in pa- tients taking oral anticoagulant therapy and un- dergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;381:1107</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref60" class="s85" target="_blank">–</a>15<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref61" class="a" target="_blank">Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple therapy in patients requiring oral anti- coagulation after drug-eluting stent implantation. J Am Coll Cardiol 2015;65:1619</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref61" class="s85" target="_blank">–</a>29<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref62" class="a" target="_blank">Gibson CM, Mehran R, Bode C, et al. Preven- tion of bleeding in patients with atrial </a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref62" class="s88" target="_blank">ﬁ</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref62" class="a" target="_blank">brillation undergoing PCI. N Engl J Med 2016;375:2423</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref62" class="s85" target="_blank">–</a>34<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref63" class="a" target="_blank" name="bookmark73">Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial </a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref63" class="s88" target="_blank">ﬁ</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref63" class="a" target="_blank">brillation. N Engl J Med 2017. </a>NEJMoa1708454<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref64" class="a" target="_blank" name="bookmark74">Lip GYH, Collet J-P, Haude M, et al. 2018 joint European consensus document on the manage- </a>ment of antithrombotic therapy in atrial <a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref64" class="s88" target="_blank">ﬁ</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref64" class="a" target="_blank">brillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of </a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref64" target="_blank">the</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s89" style="padding-top: 5pt;padding-left: 41pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref64" class="a" target="_blank">uropean Heart Rhythm Association (EHRA), Euro- pean Society of Cardiology Working Group on Thrombosis, European Association of Percuta- neous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA). Europace 2018 July 21 [E-pub ahead of </a>print]<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 41pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref65" class="a" target="_blank" name="bookmark75">Eikelboom JW, Connolly SJ, Bosch J, et al., for the COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017;377:1319</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref65" class="s85" target="_blank">–</a>30<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 41pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref66" class="a" target="_blank">Moon JY, Nagaraju D, Franchi F, Rollini F, Angiolillo DJ. The role of oral anticoagulant ther- apy in patients with acute coronary syndrome. Ther Adv Hematol 2017;8:353</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref66" class="s85" target="_blank">–</a>66<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 41pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref67" class="a" target="_blank" name="bookmark76">Johnston A, Jones WS, Hernandez AF. The ADAPTABLE trial and aspirin dosing in secondary prevention for patients with coronary artery dis- ease. Curr Cardiol Rep </a>2016;18:81<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 41pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref68" class="a" target="_blank" name="bookmark77">Capodanno D, Angiolillo DJ. Aspirin for pri- mary cardiovascular risk prevention and beyond in diabetes mellitus. Circulation 2016;134:1579</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref68" class="s85" target="_blank">–</a>94<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 41pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref69" class="a" target="_blank">Capodanno D, Patel A, Dharmashankar K, et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus pa- tients with coronary artery disease. Circ Cardiovasc Interv 2011;4:180</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref69" class="s85" target="_blank">–</a>7<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 41pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref70" class="a" target="_blank" name="bookmark78">Gargiulo G, Windecker S, Vranckx P, Gibson CM, et al. A Critical Appraisal of Aspirin in Secondary Prevention. Circulation 2016;134: 1881</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref70" class="s85" target="_blank">–</a>906<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 41pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref71" class="a" target="_blank">Capodanno D, Mehran R, Valgimigli M, et al. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nat Rev Cardiol 2018;15:480</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref71" class="s85" target="_blank">–</a>96<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 41pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref72" class="a" target="_blank" name="bookmark79">Vranckx P, Valgimigli M, Jüni P, et al., for the GLOBAL LEADERS Investigators. Ticagrelor plus aspirin for 1 month, followed by ticagrelor mon- otherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 2018;392: 940</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref72" class="s85" target="_blank">–</a>9<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 41pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref73" class="a" target="_blank" name="bookmark80">Motovska Z, Hlinomaz O, Miklik R, et al. Pra- sugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percu- taneous coronary intervention: clinical perspec- tive. Circulation 2016;134:1603</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref73" class="s85" target="_blank">–</a>12<span style=" color: #000;">.</span></p></li><li><p style="padding-top: 3pt;padding-left: 41pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref74" class="a" target="_blank" name="bookmark81">Schulz S, Angiolillo DJ, Antoniucci D, et al. Randomized comparison of ticagrelor versus pra- sugrel in patients with acute coronary </a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref74" target="_blank">syndrome</a></p><p class="s89" style="padding-top: 5pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref74" class="a" target="_blank">and planned invasive strategy</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref74" class="s85" target="_blank">—</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref74" class="a" target="_blank">design and ratio- nale of the Intracoronary Stenting and Antith- rombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial. J Cardiovasc Transl Res 2014;7:91</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref74" class="s85" target="_blank">–</a>100<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 4pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref75" class="a" target="_blank" name="bookmark82">Berwanger O, Nicolau JC, Carvalho AC, et al., for the TREAT Study Group. Ticagrelor vs clopi- dogrel after </a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref75" class="s88" target="_blank">ﬁ</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref75" class="a" target="_blank">brinolytic therapy in patients with st-elevation myocardial infarction: a randomized clinical trial. JAMA Cardiol 2018;3:391</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref75" class="s85" target="_blank">–</a>9<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 4pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref76" class="a" target="_blank" name="bookmark83">Cuisset T, Deharo P, Quilici J, et al. Bene</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref76" class="s88" target="_blank">ﬁ</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref76" class="a" target="_blank">t of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) ran- domized study. Eur Heart J 2017;38:3070</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref76" class="s85" target="_blank">–</a>8<span style=" color: #000;">.</span><a name="bookmark84">&zwnj;</a></p></li><li><p class="s89" style="padding-top: 4pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref77" class="a" target="_blank" name="bookmark85">Sibbing D, Aradi D, Jacobshagen C, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergo- ing percutaneous coronary intervention (TROP- ICAL-ACS): a randomised, open-label, multicentre trial. Lancet 2017;390:1747</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref77" class="s85" target="_blank">–</a>57<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 4pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref78" class="a" target="_blank" name="bookmark86">Notarangelo FM, Maglietta G, Bevilacqua P, et al. Pharmacogenomic approach to selecting antiplatelet therapy in acute coronary syndromes: PHARMCLO trial. J Am Coll Cardiol 2018;71: 1869</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref78" class="s85" target="_blank">–</a>77<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 4pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref79" class="a" target="_blank" name="bookmark87">Price MJ, Angiolillo DJ. Pharmacogenomic testing to select antiplatelet therapy. J Am Coll Cardiol 2018;71:1878</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref79" class="s85" target="_blank">–</a>81<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 4pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref80" class="a" target="_blank" name="bookmark88">Moon JY, Franchi F, Rollini F, et al. Role of genetic testing in patients undergoing percuta- neous coronary intervention. Expert Rev Clin Pharmacol 2018;11:151</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref80" class="s85" target="_blank">–</a>64<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 4pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref81" class="a" target="_blank" name="bookmark89">Giustino G, Chieffo A, Palmerini T, et al. Ef</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref81" class="s88" target="_blank">ﬁ</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref81" class="a" target="_blank">- cacy and safety of dual antiplatelet therapy after complex PCI. J Am Coll Cardiol 2016;68:1851</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref81" class="s85" target="_blank">–</a>64<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 4pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref82" class="a" target="_blank" name="bookmark90">Hahn J-Y, Song Y Bin, Oh J-H, et al. 6-month versus 12-month or longer dual antiplatelet ther- apy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART- DATE): a randomised, open-label, non-inferiority trial. Lancet 2018;391:1274</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref82" class="s85" target="_blank">–</a>84<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 4pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref83" class="a" target="_blank">Valgimigli M, Patialiakas A, Thury A, et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol 2015;65:805</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref83" class="s85" target="_blank">–</a>15<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 4pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref84" class="a" target="_blank">Ariotti S, Adamo M, Costa F, et al. Is bare- metal stent implantation still justi</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref84" class="s88" target="_blank">ﬁ</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref84" class="a" target="_blank">able in high bleeding risk patients undergoing percutaneous coronary intervention? J Am Coll Cardiol Intv 2016;9:426</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref84" class="s85" target="_blank">–</a>36<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 5pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref85" class="a" target="_blank" name="bookmark91">Urban P, Meredith IT, Abizaid A, et al. Poly- mer-free Drug-coated coronary stents in patients at  high bleeding  risk. N Engl J  Med 2015;373: 2038</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref85" class="s85" target="_blank">–</a>47<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref86" class="a" target="_blank" name="bookmark92">Varenne O, Cook S, Sideris G, et al. Drug- eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single- blind trial. Lancet 2018;391:41</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref86" class="s85" target="_blank">–</a>50<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref87" class="a" target="_blank" name="bookmark93">Capodanno D, Angiolillo DJ. Tailoring dura- tion of DAPT with risk scores. Lancet 2017;389: 987</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref87" class="s85" target="_blank">–</a>9<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref88" class="a" target="_blank" name="bookmark94">Lopes RD, Vora AN, Liaw D, et al. An open- label, 2</a> <a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref88" class="s85" target="_blank">x </a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref88" class="a" target="_blank">2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with</a> atrial <a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref88" class="s88" target="_blank">ﬁ</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref88" class="a" target="_blank">brillation and acute coronary syndrome and/or percutaneous coronary intervention: ratio- nale and design of the AUGUSTUS trial. Am Heart J 2018;200:17</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref88" class="s85" target="_blank">–</a>23<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref89" class="a" target="_blank" name="bookmark95">Vranckx P, Lewalter T, Valgimigli M, et al. Evaluation ofthe safety and ef</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref89" class="s88" target="_blank">ﬁ</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref89" class="a" target="_blank">cacy of an edoxaban- based antithrombotic regimen in patients with atrial</a> <a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref89" class="s88" target="_blank">ﬁ</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref89" class="a" target="_blank">brillation following successful percutaneous coronary intervention (PCI) with stent placement: rationale and design of the ENTRUST-AF PCI trial. Am Heart J 2018;196:105</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref89" class="s85" target="_blank">–</a>12<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref90" class="a" target="_blank" name="bookmark96">Rossini R, Tarantini G, Musumeci G, et al. A multidisciplinary approach on the perioperative antithrombotic management of patients with coronary stents undergoing surgery. J Am Coll Cardiol Intv 2018;11:417</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref90" class="s85" target="_blank">–</a>34<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref91" class="a" target="_blank">Godier A, Fontana P, Motte S, et al. Manage- ment of antiplatelet therapy in patients undergo- ing elective invasive procedures: proposals from the French Working Group on perioperative he- mostasis (GIHP) and the French Study Group on thrombosis and hemostasis (GFHT). In collabora- tion with the French Society for Anesthesia and Intensive Care (SFAR). Arch Cardiovasc Dis 2018; 111:210</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref91" class="s85" target="_blank">–</a>23<span style=" color: #000;">.</span></p></li><li><p class="s89" style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;line-height: 122%;text-align: justify;"><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref92" class="a" target="_blank">Vivas D, Roldán I, Ferrandis R, et al. Manejo perioperatorio y periprocedimiento del trata- miento antitrombótico: documento de consenso de SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT y AEU. Rev Española Cardiol 2018;71:553</a><a href="http://refhub.elsevier.com/S0735-1097(18)38736-9/sref92" class="s85" target="_blank">–</a>64<span style=" color: #000;">.</span></p></li></ol><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 9pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="176" height="0" alt="image" src="j.jacc.2018.09.057/Image_031.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s91" style="padding-left: 9pt;text-indent: 0pt;line-height: 123%;text-align: left;">KEY WORDS <span class="s92">antiplatelet, bleeding, stent, thrombosis</span></p></body></html>
